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- 1 - Introduction 
Abstract 
The first description of histamine dates back to Sir Henry Dale and co-workers (Dale HH, 
1910, Kwiatkowski, 1941) who detected its presence and biological activity. Dale and 
colleagues by studying the effect of ergot extracts, identified histamine as a stimulant of 
smooth muscle in the gut and respiratory tract by induction of vasodilatation. Simultaneously, 
at the beginning of XX century, the stimulation of acid secretion in the stomach caused by 
histamine was also recognized. During the first 20 years after these discoveries other 
important histaminergic actions were identified. Lewis and Grant (LEWIS T.,   1924) 
headlines: Vascular reaction of the skin to injury. The liberation of a histamine-like substance 
in injured skin: the underlying cause of factitious urticarial and of wheals produced by 
burning, and observation upon the nervous control of skin reactions. This discovery defined 
for the first time what will be then called “triple response of Lewis. In the following years, 
despite continuous efforts and considerable improvements in the available technology, the 
experimental data showing that histamine participates in physiological processes was rather 
inconclusive. The presence of histamine in the brain, predominantly in the grey matter, was 
first shown by Kwiatkowski (Kwiatkowski, 1941), and White (White, 1959) but in 1960’s 
with the introduction of fluorimetric assay that disclosed the anatomical identity of 
catecholamine containing neurons and their projections, histamine was initially neglected 
because the assay failed to determine the location of histamine in the brain. This was because 
the reagents that were used to detect this diamine cross-reacted with spermidine — a 
uniformly distributed polyamine that occurs at high concentrations in the brain (Haas and 
Panula, 2003). But circumstantial evidence began to accumulate indicating a significant role 
for histamine, and lesion studies by Schwartz’ group, in 1974, pointed to the approximate 
location of a brain source of histamine (Garbarg et al., 1974). Later, two different and parallel 
discoveries brought to the general acceptance of the existence of central histaminergic system. 
Panula and colleagues and Watanabe and co-workers in 1984 independently demonstrated by 
means of immunohistochemistry that the tuberomamillary nucleus (TMN) in the posterior 
hypothalamus is the only source of histaminergic neurons and the origin of the widely 
distributed histaminergic projections just like the other amine systems  (Panula et al., 1984, 
Takeda et al., 1984). It is now clear that the histaminergic TMN system commands general 
states of metabolism like satiety and appetite, arousal, and of consciousness, including 
learning and memorizing both pleasurable and aversive events. 
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In my thesis, I will provide evidence that in the brain histaminergic system peripheral and 
central signals converge and that the histaminergic system orchestrates appropriate 
behavioural responses. In particular, I will present results that strongly suggest the 
involvement of histamine neurons in the pro-cognitive and antidepressant-like effects of 
oleoylethanolamide, a lipid that is normally secreted by the intestine after a fatty meal, and I 
will present data on some of the molecular mechanisms responsible for these effects. I will 
also illustrate the influence of dietary factors on stress reactivity and cognition and 
preliminary results on the role of brain histamine in such a model. 
The results exposed in this thesis may have relevance in revealing new mechanisms in the gut 
brain axis where brain histamine plays a key role as it acts as a gatekeeper of peripheral and 
central signals to elaborate the appropriate behaviour.  
1. Histamine in the Nervous System 
1.1 Anatomic Framework  
In the central nervous system, the presence of histamine is attributed at the presence of the 
histamine-releasing neurons. The amount of histamine derived by non-neuronal pool (mast 
cells) is somewhat limited under normal conditions. Other possible sources of histamine in the 
brain may include microglia and microvascular endothelial cells (Katoh et al., 2001, 
Yamakami et al., 2000).  Mast cells are relatively scarce in the brain, in comparison to other 
tissues, and their function is at present unclear. Furthermore, the amount of peripherally 
synthetized histamine not contribute to its central content due to the histamine inability to 
cross the blood brain barrier. Therefore, it can be assumed that central histaminergic function 
are due almost exclusively to histaminergic neurons (Brown and Ennis, 2001). As previously 
reported, the histamine-producing neurons are located in the small tuberomamillary nucleus 
(TMN). The name, tuberomamillary nucleus, derives from the anatomical term tuber cinerum, 
denoting an ashen swelling located rostral to the mammillary bodies and caudal to the optic 
chiasm, forming the floor of the third ventricle in the hypothalamus (Krüger and Nyland, 
1995). The TM in rats has been subdivided by Ericson et al. (Ericson et al., 1987) into three 
subgroups: (I) the medial tuberomamillary subgroup (TMM), which consists of around 600 
neurons located on either side of the mammillary recess; (II) the ventral tuberomamillary 
subgroup (TMV), which contains approximately 1500 neurons around the mamillary bodies; 
and (III) the diffuse part of the TM (TMdiff or E5), which is made up of about 100 HD-
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immunoreactive perikarya scattered within or between various hypothalamic nuclei (Inagaki 
et al., 1990). In the mouse brain the TMN is less compact and is characterized by smaller and 
fewer neuron than rat TMN (Parmentier et al., 2002). The human TMN consist of about 
64.000 neurons anatomically identified as the ventral, medial area and the lateral area 
(Airaksinen et al., 1991a).  
The histamine neurons in the TM send projections that innervate the entire brain, and parts of 
the spinal cord (Figure 1) (Panula et al., 1984, Watanabe et al., 1984). Two ascending 
pathways and one descending pathway have been identified (Panula et al., 1989). The highest 
density of histaminergic fibres are found in the hypothalamus, diagonal band, septum and 
olfactory tubercle. Moderate density of fibres is found in cerebral cortex, striatum and nucleus 
accumbens. Projections to the midbrain, brain stem, cerebellum and spinal cord tend to be of 
lower density. The hippocampal formation is most strongly innervated in the subiculum and 
dentate gyrus, with a low density of fibres present in CA3 and CA1(Brown and Ennis, 2001). 
The afferent projections to TM neurons are widespread and come from many different areas. 
Prominent sources are the infralimbic prefrontal cortex, lateral septum and preoptic nucleus 
(Ericson et al., 1991). Most of the efferent histaminergic fibres are unmyelinated and except 
for those that project to the trigeminal nucleus (Inagaki et al., 1988), do not in general form 
synaptic specializations, rather, histamine is released from varicosities located periodically 
along the axon (Takagi et al., 1986). Thus, histamine release sites and histamine receptors are 
not directly associated to one another. Rather, histamine has been proposed to act like a local 
hormone on neurons, glial cells and blood vessels in a concerted manner (Wada et al., 1991). 
In addition to histamine, the TM neurons contain several other neurotransmitters and 
modulators like GABA that is presumably released in specific brain regions to modulate 
behavioural response (Williams et al., 2014, Yu et al., 2015b). The neuropeptides GALANIN, 
thyrotropin-releasing hormone, proenkephalin-derived peptides and substance P are also 
found in various populations of histamine producing TM neurons. Most TM neurons also 
express adenosine deaminase (ADA), the enzyme that catalyses the conversion of adenosine 
to inosine (Haas and Panula, 2003).  
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Figure 1. The histaminergic system in human brain. The histaminergic fibres emanating 
from the tuberomamillary nucleus project to and arborize in the whole central nervous 
system (Haas et al., 2008).  
1.2 Histaminergic Receptors 
The basic homeostatic and higher functions, including cognition, arousal, circadian and 
feeding rhythms regulated by brain histamine are due to the action on 4 metabotropic 
receptors: H1R, H2R, H3R, H4R. All of histaminergic receptors are expressed at central level 
with different density in different brain regions (Passani and Blandina, 2011). All 
metabotropic histamine receptors (H1R-H4R) belong to the rhodopsin-like family of G protein 
coupled receptors (GPCR).  Each receptor consists of seven large transmembrane-spanning 
elements with prototypic domains (Haas et al., 2008). Three of the four histamine receptors 
that have been identified (H1–H3) are prominently expressed in the brain in specific cellular 
compartments, whereas the fourth (H4) receptor is detected predominantly in bone marrow 
and leukocytes (Haas and Panula, 2003).  
 
1.2.1 Histamine H1 Receptor 
The human H1 receptor is encoded by a gene of 56kDa composed by 487~490 amino acids 
located on chromosome 3p25 (Jongejan et al., 2005). The signal transduction of H1R is 
mainly mediated by coupling to Gq/11 proteins (Gutowski et al., 1991, Leopoldt et al., 1997, 
Selbach et al., 1997, Moniri et al., 2004), but also signals via Gi/o in some systems (Seifert et 
al., 1994, Wang and Kotlikoff, 2000), and the small G protein family, most likely through an 
indirect downstream effect (Mitchell and Mayeenuddin, 1998).  The interaction of H1 receptor 
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with Gq/11 protein and phospholipase C promotes inositol trisphosphate (IP3)-dependent 
Ca2+ release from intracellular Ca2+-stores, and also diacylglycerol formation. H1R also 
activates AMP-kinase, nuclear factor kappa B, nitric oxide synthases, and phospholipase A2 
(PLA2), which induces arachidonic acid formation (Haas et al., 2008). H1R are found 
throughout the whole body and nervous system. H1 receptors are widely distributed in 
mammalian brain (Hill, 1990, Schwartz et al., 1991). High densities are found in brain regions 
concerned with neuroendocrine, behavioural, and nutritional state control, including the 
periventricular, suprachiasmatic, and ventromedial nuclei of the hypothalamus, aminergic and 
cholinergic brainstem nuclei, thalamus, and cortex (Schwartz et al., 1991). The global loss of 
H1R in KO mice produces immunological, metabolic, and behavioural abnormalities (Masaki 
and Yoshimatsu, 2006, Hirai et al., 2004, Huang et al., 2006, Haas et al., 2008). 
 
1.2.2. Histamine H2 Receptor 
A second class of histamine receptors was identified by Black and colleagues based on the 
different pharmacological profile of the histamine receptor responsible for stimulating gastric 
acid secretion (Hill et al., 1997). The gene encoding the human H2R, which is a 40-kDa 359-
amino acid peptide, is located on chromosome 5q35.5. H2R couple to Gs proteins to stimulate 
adenylyl cyclase and increase intracellular cAMP, which activates protein kinase A (PKA) 
and the transcription factor CREB, all of which are key regulators of neuronal physiology and 
plasticity. Through H2R activation and PKA-dependent phosphorylation, histamine blocks a 
Ca2+-activated potassium conductance responsible for the neuronal excitability (Haas et al., 
2008). Independent of either cAMP or [Ca2+ ]i levels, H2R also inhibit PLA2 and release of 
arachidonic acid, which likely account for the opposing physiological responses elicited by 
H1R and H2R in many tissues (Traiffort et al., 1992). Like the histamine H1 receptor, the H2 
receptor has a widespread expression in the brain and spinal cord, particularly high densities 
are found in the basal ganglia and in parts of the limbic system such as the hippocampal 
formation and amygdala. In contrast to H1 receptors, H2 receptors are present in low densities 
in septal areas, hypothalamic and thalamic nuclei. H1 and H2 receptors are colocalized in 
several areas of the brain including pyramidal and granule cells in the hippocampal formation 
and in the other aminergic cell where the receptors can act synergistically, e.g. in the 
stimulation of cAMP production (Brown and Ennis, 2001). Mice deficient in H2R function 
exhibit selective cognitive deficits along with an impairment in hippocampal LTP (Dai et al., 
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2007) and with abnormalities in nociception (Mobarakeh et al., 2005, Mobarakeh et al., 2006) 
and gastric and immune functions (Teuscher et al., 2004). 
1.2.3 Histamine H3 Receptor 
Histamine H3 receptor in the brain were detected in1983 by the group of J.C. Schwartz in 
Paris proved its neurotransmitter function as auto- as well as hetero-receptor at pre- and 
postsynaptic membranes and revealed its profound influence on different neurotransmitter 
balances (Panula et al., 2015). The gene (Hrh3) encoding human H3R, a 70-kDa 445-amino 
acid peptide, is located on chromosome 20q13.33. H3R negatively couple through pertussis 
toxin-sensitive Gi/o proteins to N- and P-type Ca2+ channels and to adenylyl cyclase. Through 
extensive cross-talks with other GPCRs, they can also engage Gq/11 signalling and activate 
PLA2, Akt/GSK3, and MAP kinase pathways, all of which play important roles in axonal and 
synaptic plasticity and a variety of brain disorders (Haas et al., 2008). The histamine H3 
receptor is located on histaminergic neuron somata, dendrites and axon varicosities, as well as 
on the axon varicosities and somata of other neurons, providing negative feedback to inhibit 
histamine synthesis and the release of histamine or other transmitters, including glutamate 
(Brown and Reymann, 1996, Doreulee et al., 2001), acetylcholine (Arrang et al., 2007, 
Passani and Blandina, 1998) and GABA (Jang et al., 2001, Yamamoto et al., 1997). In 
keeping with their role as auto- and hetero-receptors, H3R  are heterogeneously distributed 
among areas known to receive histaminergic projections (Hu and Chen, 2017). High densities 
are found particularly in anterior parts of the cerebral cortex, hippocampus, amygdala, nucleus 
accumbens, striatum, olfactory tubercles, cerebellum, substantia nigra, and brain stem. In the 
TMN, H3R reside on perikarya of histaminergic neurons. Loss of H3R function in KO mice is 
associated with behavioural state abnormalities, reduced locomotion (Toyota et al., 2002), a 
metabolic syndrome with hyperphagia, late-onset obesity, increased insulin and leptin levels 
(Tokita et al., 2006, Yoshimoto et al., 2006), and an increased severity of neuroinflammatory 
diseases (Teuscher et al., 2007).  
1.2.4 Histamine H4 Receptor 
Six independent laboratories contributed to the identification and cloning of the H4 receptor 
(Nakamura et al., 2000, Oda et al., 2000, Liu et al., 2001, Morse et al., 2001, Nguyen et al., 
2001, Zhu et al., 2001, O'Reilly et al., 2002). The human H4 receptor gene is present on 
chromosome 18q11.2 and is a 44 kDa 390-amino-acid polypeptide. Like H3R, the H4 receptor 
is coupled to pertussis toxin sensitive Gi/o protein with inhibitory effect on cAMP 
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accumulation (Oda et al., 2000, Leurs et al., 2009). H4 receptor expression has been observed 
in eosinophils, T cells, dendritic cells, basophils, and mast cells (Liu et al., 2001, Gantner et 
al., 2002, O'Reilly et al., 2002, Hofstra et al., 2003), but its expression in the central nervous 
system remains controversial. In the human brain, expression of H4 receptor mRNA has been 
reported in the amygdala, cerebellum, corpus callosum, cortex frontal cortex, hippocampus, 
and thalamus (Strakhova et al., 2009) but, results obtained with analyses of mRNA expression 
does not always reflect results obtained with immunohistochemistry, therefore there is a 
debate about H4R in SNC that needs further research (Panula et al., 2015). 
 
1.3 Homeostatic Histaminergic Functions 
The morphology of brain histaminergic system with a compact group of cells and a capillary 
distribution of varicose fibres suggest its action as a normative centre for the brain activity. 
Pharmacological studies in intact and histamine-deficient animals as well as humans link 
brain histamine with homoeostatic brain functions and neuroendocrine control. Brain 
histamine controls behavioural responses, biological rhythms, body weight, energy 
metabolism, thermoregulation, fluid balance, stress, and reproduction (Hough, 1988, Schwartz 
et al., 1991, Parmentier et al., 2002). 
Recently, our laboratory demonstrated functional differences in TMN neurons, suggesting 
that histaminergic neurons are organized in distinct subpopulation impinging on different 
brain regions (Giannoni et al., 2009, Blandina et al., 2012).  
1.3.1 Sleep and Wakefulness 
Histaminergic neurons help sustain wakefulness, several studies corroborate this hypothesis; 
in H1R-KO mice the sleep-wake cycle is impaired, and the waking promotion induced by H3R 
antagonist is abolished (Huang et al., 2006, Lin et al., 2002). During waking c-fos expression 
increases in TMN neurons (Lin, 2000, Nelson et al., 2002, Nelson et al., 2003, Scammell et 
al., 2000, Sherin et al., 1998, Vanni-Mercier et al., 2003). The regulation of the transition 
between wakefulness and sleep involves antagonist influences of sleep-promoting VLPO 
neurons, which provide inhibitory GABA- and galanin-mediated inputs to TMN and 
brainstem cholinergic and monoaminergic groups, and excitatory effects of orexin (Hcrt/Orx) 
neurons on TMN and other wake-active neuronal groups (Benarroch, 2010).  TMN neurons 
become active just after waking and fire at an average rate of about 5 Hz, and their activity is 
suppressed during sleep (Sakai et al., 2010, Saper et al., 2010, Takahashi et al., 2006). A 
 
- 8 - Introduction 
recent elegant work by Wisden and co-workers demonstrated that zolpidem, a GABAA 
receptor-positive modulator, needs to work on specific cell types of the brain, including 
histaminergic neurons, to induce sleep, without reducing the power of the sleep, hence 
improving sleep quality (Uygun et al., 2016). Furthermore, the same laboratory showed that 
wake-active histaminergic neurons generate a paracrine GABAergic signal that serves to 
provide a brake on over-activation from histamine, but could also increase the precision of 
neocortical processing (Yu et al., 2015b). 
1.3.2 Thermoregulation 
The key anatomical sites that control thermoregulation are under histaminergic innervation.  
The control centres of thermoregulation are located in the anterior preoptic area 
(thermoregulator rostral centre) and in posterior hypothalamic area (thermoregulator  caudal 
centre) (Nieuwenhuys et al., 2008). Central administration of histamine in freely moving 
animals causes hypothermia or biphasic responses, hypo- followed by hyperthermia (Clark et 
al., 1975, Clark and Cumby, 1976, Cote and Harrington, 1993). Hyperthermia, in turn, 
facilitates neuronal histamine release (Kanamaru et al., 2001). Activation of H1Rs and H2Rs 
in the anterior hypothalamus/preoptic area and posterior hypothalamus respectively induced 
hypothermia (Benarroch, 2010, Clark and Cumby, 1976).  By H1Rs and H2Rs agonist 
actions, histamine regulates body temperature and clock neurons, suggesting an evolutionary 
conserved link between histamine, circadian rhythms, and temperature control. 
1.3.3 Fluid Balance 
Histamine elicits drinking following injection into the cerebral ventricles or into several 
hypothalamic sites (Gerald et al., 1972, Leibowitz, 1973). In addition, histamine increases the 
release of vasopressin and decreases urine output via both H1 and H2 receptors (Bhargava et 
al., 1973, Bennett and Pert, 1974, Kjaer et al., 1994). Histamine also stimulates vasopressin 
release indirectly via a local release of noradrenaline (Bealer, 1993, Bealer and Abell, 1995). 
A physiological role for central histamine in the control of fluid balance is suggested by the 
findings that 24 or 48 h of dehydration increases synthesis and release of histamine in the 
hypothalamus (Kjaer et al., 1994, Kjaer et al., 1995). Furthermore, blockade of histamine 
synthesis by -FMH, activation of presynaptic H3 autoreceptors or antagonism of 
postsynaptic histamine receptors all strongly depress dehydration-induced vasopressin release 
(Kjaer et al., 1994). Dehydration induced renin release also appears to involve central 
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histamine activation of the sympathetic nervous system (Kjaer et al., 1998, Matzen et al., 
1990). 
1.3.4 Feeding and Energy Metabolism 
The evidence for histamine involvement in food intake is nowadays very consistent (Provensi 
et al., 2016, Provensi et al., 2014). Early studies demonstrated that i.c.v injection of histamine, 
loading with histamine precursor L-histidine or application of the H3 receptor antagonist 
thioperamide suppress feeding (Cohn et al., 1973, Sheiner et al., 1985, Machidori et al., 1992, 
Ookuma et al., 1993), whereas i.c.v infusions of a-FMH or H1 receptors antagonists increase 
food intake (Sakata et al., 1988b, Fukagawa et al., 1989, Ookuma et al., 1989, Sakata et al., 
1988a). However, the role of histamine is not restricted to feeding control but also the 
regulation of body weight and adiposity by modulation of peripheral energy. Many of the 
central hypothalamic areas involved in regulating feeding, including the arcuate, ventromedial 
(VMH) and paraventricular (PVN) nucleus and lateral hypothalamic perifornical area (LHA), 
are densely innervated by histamine containing fibres and show a high density of H1Rs 
(Panula et al., 1989). Early work suggested that histamine-mediated suppression of food 
intake was controlled by the VMH as microinfusion of H1R antagonists into the VMH but not 
PVN or LH elicited feeding responses and increases both meal size and duration  (Fukagawa 
et al., 1989, Sakata et al., 2003). Likewise, electrophoretic application of H1R antagonists 
suppressed the firing of glucose-responsive units in the VMH but not in the LHA or PVN 
(Fukagawa et al., 1989). Another site of importance in the histamine control of food intake is 
the mesencephalic trigeminal nucleus. Bilateral injections of a-FMH into this region reduced 
eating speed and prolonged meal duration while leaving meal size unaltered. Feeding induced 
increases in histamine turnover in both the trigeminal nucleus, which controls mastication, 
and the ventromedial area, which is considered as a satiety centre (Fujise et al., 1998). In our 
laboratory, we recently showed that the PVN as well takes part into the histaminergic control 
feeding behaviour as histamine released in the PVN activates oxytocin neurons (Provensi et 
al., 2014) that in turn exert hypophagic behaviour (Gaetani et al., 2010). Furthermore, the 
orexigenic actions of orexins/hypocretins (Jørgensen et al., 2005) and the anorexigenic effects 
of leptin (Toftegaard et al., 2003) and glucagon-like peptide-1 (GLP-1), which depend on 
CRH released by PVN neurons (Gotoh et al., 2005), are all blunted or absent by 
pharmacological or genetic loss of H1R function. Ghrelin, another peptide of peripheral 
origin, does not affect histamine release, suggesting that ghrelin may act on a parallel, 
different mechanism that controls food intake (Ishizuka et al., 2006).  
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Most experimental observations in rodents agree that blockade of brain H3 receptor, hence 
increasing histamine release, decreases energy intake, body weight and plasma triglycerides 
(Hancock and Brune, 2005). Also, they increase histamine release from the hypothalamus, 
they reduce energy intake in normal and leptin-resistant mice with diet induced obesity 
(Ishizuka et al., 2008), and decrease food intake in wild type mice (Provensi et al., 2014).   
 
   
Figure 2. Key brain areas involved in the regulation of feeding and their innervation by 
histaminergic fibres (Panula and Nuutinen, 2013).  
From the pharmacological point of view the importance of histamine in the regulation of 
feeding behaviour came from the observation that increased weight is a common adverse 
effect of many classic antipsychotic drugs and atypical antipsychotics that depends on their 
affinity as antagonists at the H1Rs (Kroeze et al., 2003). Preclinical studies showed that 
activation of histamine neurons induces the arousal state during food anticipation (Inzunza et 
al., 2000, Angeles-Castellanos et al., 2004), and during the appetitive phase that precede food 
consumption (Passani and Blandina, 2011). 
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2.  Cognitive functions of brain histamine 
The regulation of memory consolidation by histamine is a topic of much recent research and a 
new role for the brain histaminergic system is emerging, as a gateway between peripheral 
signals and the elaboration of both aversive and emotionally neutral memories (Passani et al., 
2017). 
Memory is not a unitary faculty of the mind but is a complex process composed and 
coordinated by multiple systems, distinct brain regions and pathways involves. Two 
memory systems have been described: declarative  and procedural or ‘habit’ memory system 
(Izquierdo et al., 2006b). Declarative memory (“knowing that”) refers to conscious memory 
for events and facts, is assessed by explicit tests of recall and recognition, and depends upon 
medial temporal lobe and diencephalic brain structures. Procedural memory (“knowing how”) 
refers to unconscious memory, is assessed by experience-dependent learning of skilled 
performance, and depends on structures in the basal ganglia, cerebellum, and neocortex 
(Gabrieli, 1998). The memory systems of the mammalian brain operate independently and in 
parallel to support behaviour (Poldrack and Packard, 2003, McDonald and Hong, 2013, 
Packard and Goodman, 2013). 
Procedural or working memory (WM) was considered as overlapping with immediate 
memory or short-term memory (STM). STM was assumed to be essential for acquisition and 
perhaps subsequent long-term memory (LTM) formation.  
It is generally accepted that the STM, that lasts minutes or few hours, may be converted in 
LTM that persists for days, weeks or more, by a specific sequence of events called 
consolidation which starts immediately after the acquisition phase (Izquierdo et al., 1999, 
McGaugh, 2000). Not all information reaching the CNS is stored; most inputs are filtered 
away by the attentional and emotional processes after the acquisition phase (Cahill and 
McGaugh, 1998). Only memories relevant for cognition, emotionally salient, or derived from 
strong sensory inputs are consolidated in LTMs. Forgetting mean entails screening, since only 
memories previously selected persist, are stored and retrieved by chains of cause and effect 
controlled by a range of factors that operate simultaneously at many different levels often 
implicit, but sometimes explicit. The brain systems responsible for learning and storing 
memories have a mechanism for preventing information overload (Izquierdo et al., 2006b). 
Memory can be modulated by experiences occurring about the time when it is learned, 
consolidated or retrieved (Cahill and McGaugh, 1998, Kandel and Squire, 2000).  
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2.1 Recognition Memory 
Recognition memory involves at least two separable processes, familiarity discrimination and 
recollection and more complex aspects of contextual, associative and spatial aspects (Brown 
and Banks, 2015). Types of stimuli, single or multi-item, associative or non-associative 
stimuli, and types of information being stored, for example, the ‘what’, ‘when’, and ‘where’ 
of episodic-like memories or the modality of the sensory input allows the distinctions between 
types of memory process.  
Discrimination for visual stimuli seems to be affected by a system centred on the perirhinal 
cortex of the temporal lobe (Brown and Banks, 2015). Regions other than perirhinal cortex 
may also be involved in recognition memory processes: when a recognition memory task is 
solved using recollection or association concerning a presented stimulus, the recognition 
memory predicts hippocampal involvement (Brown et al., 2010). The hippocampus is 
involved in recognition memory using multiple items and associative or spatial information 
(Aggleton and Brown, 2006, Dere et al., 2006, Eichenbaum et al., 2007, Murray and 
Ranganath, 2007, Squire et al., 2007, Winters et al., 2008). In particular, lesions of the rat 
hippocampus impair recognition memory that requires spatial information; location tasks are 
impaired by hippocampal lesions while perirhinal lesions have no effect (Warburton and 
Brown, 2010).  
Functional imaging in human subjects has implicated the prefrontal cortex in recognition 
memory processes (O'Neil et al., 2012). The role of the rodent medial prefrontal cortex in 
recognition memory has been extensively studied. Large lesions of the prefrontal cortex, 
which included the anterior cingulate, prelimbic and infralimbic cortices, or which centred on 
the ventral medial prefrontal cortex, produced recognition impairments (Kolb et al., 1994, 
Ragozzino et al., 2002). The medial prefrontal cortex has been implicated in attentional 
processing (Muir, 1996, Chudasama and Robbins, 2003), and play an important role in 
temporal order memory (Mitchell and Laiacona, 1998, Hannesson et al., 2004, Chiba et al., 
1997). Lesions in the medial prefrontal cortex impaired temporal order memory task (Barker 
et al., 2007, Devito and Eichenbaum, 2011) but not induces deficits in the recognition or 
location tasks (Barker et al., 2007). Moreover, in humans and non-human primates damage to 
the medial dorsal thalamus (MD nucleus) produces recognition memory deficits (Victor, 
1987, Parker et al., 1997, Warburton and Brown, 2015).  
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2.2 Fear Memory 
Forming associations about events and then consolidating memories of those associations is 
an important strategy for survival. However, in traumatic situations, these associations 
sometimes become overly consolidated and then, potentially, are resistant to extinction over 
time, resulting in fear-related disorders (Parsons and Ressler, 2013).  But fear, in general, has 
a strong survival value. The lack of fear, also called recklessness or mindlessness in humans, 
is inherently dangerous and potentially lethal (Izquierdo et al., 2016). Therefore, in both 
cases, over-consolidation/resistant-extinction and recklessness/loss of fear are two side of the 
same coin, dangerous in the same way. 
The acquisition and memory of conditioned fear depend on both hippocampus and amygdala, 
as lesion studies (Lorenzini et al., 1996b, Lorenzini et al., 1996a, Sacchetti et al., 1999, 
Sacchetti et al., 2002) and biochemical studies (Trifilieff et al., 2007) indicate. The sensory-
related information from hippocampus and amygdala presumably originates in the 
mesencephalic reticular formation and ventral tegmental area (VTA), which receive it, in turn, 
from collaterals of the sensory pathways (BUSER and ROUGEUL, 1961, GREEN and 
MACHNE, 1955, MACHNE and SEGUNDO, 1956). The hippocampus and the basolateral 
amygdala (BLA) together with the ventro-medial prefrontal cortex (vmPFC) orchestrate 
memory formation (Izquierdo et al., 2016). Also the periaqueductal grey (PAG), is a brain 
region that conveys aversive signals to the amygdala. The PAG is known as an output 
structure for various conditioned fear responses, it receives a strong nociceptive input from 
the spinal and trigeminal dorsal horn (Gross and Canteras, 2012) and a recent study found that 
temporary pharmacological inactivation of PAG reduces shock-evoked responding in 
amygdala neurons and the acquisition of fear learning (Johansen et al., 2011).  
2.3 How to evaluate memory in rodents: most widely used paradigms 
Fear learning is usually studied by classical (Pavlovian) or instrumental association between 
the environment or changes in the environment (conditioned stimulus, CS) and a fearsome 
stimulus (usually one or more mild foot shocks; unconditioned stimulus, US). This type of 
learning represents situations in humans in which initially neutral stimuli become threatening 
through pairing with other stimuli and generate fear, a human emotion that guides much of 
our behaviour and is crucial for survival (Izquierdo et al., 2016).  
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In the fear conditioning paradigm, the animals are placed in a new environment (context) 
were they receive a mild aversive stimulus such as a foot shock (US) associated with another 
stimulus such as tone or light (CS), that usually does not elicit a response. Following learning, 
the presentation of the CS alone generates various visceral and behavioural conditioned fear 
responses. The term fear response is used to refer specifically to measurable responses that 
occur in response to threat and not to the conscious feelings of fear: called freezing behaviour.  
Freezing behaviour (conditioned response, CR), is a generalized immobility caused by a 
generalized tonic response of the animals' skeletal musculature except those muscles used in 
breathing (Herry and Johansen, 2014, Izquierdo et al., 2016).  
Promnesic agents are expected to increase, whereas amnesic manipulations to reduce freezing 
behaviour (Wehner and Radcliffe, 2004, Curzon  et al., 2009).  
The most widely used instrumental fear conditioning is one-trial inhibitory avoidance (IA) 
(Gold, 1986, Izquierdo et al., 2006a, Izquierdo and Medina, 1997) which used to be called 
“passive avoidance” in opposition to the “active avoidance” tasks in which animals have to 
perform some movement to avoid the foot shocks. In the “passive” tasks animals have to 
withhold stepping through a hole into a dark compartment, or stepping down from a platform 
onto a grid, to access the shock compartment; the required response is to remain in the safe, lit 
compartment or on the start platform. Animals learn to avoid stepping through or stepping 
down, but they are not in any way refrained from moving or behave in any way passively. In 
fact, they move a lot while on the platform or in the lit compartment (Netto and Izquierdo, 
1985). When re-tested, an increase in the latency to step-through or to step-down is related as 
a measure of learning (Izquierdo and McGaugh, 2000).  
During the last decade the ‘what’, ‘where’ and ‘when’ (WWWhen) episodic-like memory 
(ELM) task, which is based on the object recognition paradigm, has been utilized for the 
cognitive phenotyping of mouse mutants and transgenic mouse models of neuropsychiatric 
diseases. It was also widely used to identify the neuroanatomical, electrophysiological and 
pharmacological foundations of ELM formation, retention and retrieval (Binder et al., 
2015).  The object recognition paradigm is one-trial task, does not involve learning of rules, 
does not require reinforces and is purely based on the innate preference of the rodents to 
explore the novel object. Thus, a rodent that remembers the familiar object will spend more 
time exploring a novel object rather than the familiar one (Leger et al., 2013). The preference 
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for the novel object is the result of incidental learning occurring during the sample phase and 
exploratory behaviour during the testing phase (Jablonski et al., 2013).  
2.4 The role of central histaminergic system in memory and cognition 
Recent findings have reasserted the role of histamine in the regulation of memory 
consolidation first proposed in 1986 in an inhibitory avoidance task in rats (Passani et al., 
2017). The first description on the role of histamine in memory process came from de 
Almeida and Izquierdo, 1986 (de Almeida and Izquierdo, 1986); the authors demonstrated 
that the infusion of histamine in the lateral ventricles facilitates fear memory process when 
tested in the inhibitory avoidance paradigm. At that time, though, it was not entirely clear, 
however, whether histamine had a physiological role in memory modulation. We now know 
that histamine exerts different effects in different brain regions and different modulatory 
actions depending on the type of memory task and the phase of memorization (Passani et al., 
2017, Passani et al., 2007). In the hippocampus and amygdala the histaminergic 
neurotransmission exerts different actions. Histamine or H3 antagonists infusion in the 
hippocampus ameliorated the performances in spatial learning (Huang et al., 2003). Histamine 
infusion in the dorsal hippocampus facilitates fear memory by activating H2 receptor (da Silva 
et al., 2006), whereas in the ventral hippocampus  H1 receptor inhibits fear memory (Alvarez 
and Banzan, 2008).  
When histamine was locally injected into dorsal and ventral regions of the hippocampus 
improvements in the rats performances in the inhibitory avoidance test (Alvarez and Banzan, 
2008, Alvarez and Banzan, 2001, Alvarez and Banzan, 1996, da Silva et al., 2006) and also in 
the radial-maze tasks (Huang et al., 2003, Yamamoto et al., 2007) were observed. Conversely, 
blockade of endogenous histamine production by α-FMH infusion into the ventricles inhibits 
the consolidation of IA, which is known to be sustained by both the BLA and the 
hippocampus (Izquierdo et al., 2006a, Izquierdo and Medina, 1997, Izquierdo et al., 1992, 
McGaugh, 2015, McGaugh, 2000).   
The H1 and H2 histamine receptors in BLA, hippocampus, and vmPFC facilitate memory 
consolidation in the inhibitory avoidance task (IA) and contextual fear conditioning (CFC), 
and their specific antagonists have an opposite effect in the consolidation of different tasks 
(Benetti and Izquierdo, 2013, Benetti et al., 2012, Fiorenza et al., 2012).  
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A recent, seminal observation by Benetti et al. (2015) (Benetti et al., 2015) revealed that 
histaminergic neurotransmission provides the brain with the plasticity necessary to ensure 
memorization of emotionally salient events, through recruitment of alternative circuits.  The 
authors found that the integrity of the brain histaminergic system is necessary for long-term, 
but not for short-term memory of step-down inhibitory avoidance. In addition, they observed 
that phosphorylation of cyclic adenosine monophosphate responsive-element-binding protein 
(CREB), a crucial mediator in long-term memory formation (Bernabeu et al., 1997, Josselyn 
et al., 2004) correlates anatomically and temporally with histamine-induced memory retrieval, 
showing the active involvement of histamine in the CA1 region of the hippocampus and in the 
basolateral amygdala in different phases of memory consolidation 
3.  Disorders associated with brain histamine 
No disease entity has so far been linked specifically or selectively to brain histamine 
dysfunction, but histamine dysfunction may thus be a precipitating factor for epigenetic 
disease susceptibility, severity, and progression.  
Histamine as the major wake-promoting neurotransmitter in the CNS and plays a role in the 
pathogenesis of sleep disorders. Cerebrospinal fluid histamine levels are decreased in people 
with idiopathic hypersomnia or narcolepsy, supporting the concept that histamine in humans 
promotes alertness and wakefulness (Nishino et al., 2009, Kanbayashi et al., 2009). 
Narcolepsy is a sleep disorder characterized by excessive daytime sleepiness, catalepsy and 
narcoleptic episodes. Insomnia is usually treated with benzodiazepines, whereas narcolepsy 
was treated until recently with wakefulness-promoting compounds, like modafinil, and 
amphetamines that modulate the dopaminergic system. In 2015, the European Medicines 
Agency (EMA) has recommended pitolisant, a first-in-class medicine that acts on histamine 
H3 receptors in the brain that blocks autoreceptors, for the treatment of narcolepsy with or 
without cataplexy.  
In contrast to other aminergic systems, both histamine and the levels of its metabolites 
increase in the spinal fluid with increasing age (Prell et al., 1988). In Alzheimer's disease, 
several subcortical ascending projections, including the histaminergic neurons, display 
degeneration and tangle formation (Swaab et al., 1998). In the hypothalamus, neurofibrillary 
tangles occur exclusively in the TM nucleus (Airaksinen et al., 1991b) and histamine levels is 
reduced in different brain areas including hippocampus, hypothalamus, frontal and temporal 
cortex (Panula et al., 1998, Shan et al., 2012) suggesting that histaminergic neurons undergo 
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degeneration and contribute to cognitive decline in this disorder. H3R antagonists improve 
cognitive performance in experimental animals. So far, though, clinical trials with these 
compounds have proven unsuccessful (NIH website). The TM neurons seem morphologically 
normal in patients with Parkinson’s disease (PD) (Nakamura et al., 1996), and normal 
histidine decarboxylase activity has been observed (Garbarg et al., 1983) .  In contrast, 
histamine levels are markedly increased in the substantia nigra, putamen and globus pallidus 
(Rinne et al., 2002), but only modest changes in t-MeHA, the main metabolite of histamine, 
and histamine-N-methyltransferase activity (Fogel et al., 1994) indicating that the increased 
histamine might not be present in the releasable pool in the brains of these patients. This 
might be due to the limited capacity of the vesicular monoamine transporter VMAT-2 to take 
up histamine into the vesicle.  
Thus, the alteration in histamine may be a direct consequence of dopamine deficiency, a 
hallmark of Parkinson’s disease. The abnormalities in the histaminergic system is highlighted 
in PD patients which often experienced fragmented sleep and insomnia. Alteration in the 
histaminergic system is also revealed in receptor binding profile. H3R binding is abnormally 
high in the Parkinsonian substantia nigra (Anichtchik et al., 2000), and the same phenomenon 
is seen in rats after depletion of nigrostriatal dopamine stores using 6-OHDA (Ryu et al., 
1994). However, H3R antagonists improve motor coordination in neonatally 6-OHDA-
lesioned rats, whereas imetit, an H3R agonist, attenuates 3,4-dihydroxyphenylalanine (l-
DOPA)-induced increases in striatal extracellular dopamine and dyskinesia (Nowak et al., 
2008). Histamine, via activation of H3Rs, thus regulates the cortico–striato–nigral system at 
all levels (Panula and Nuutinen, 2013).  
The first antipsychotics were developed as antihistaminic compounds, before dopamine was 
recognized as a key neurotransmitter in the brain. It is now known that the atypical 
antipsychotic drugs have an affinity for many different receptors, including those for 
serotonin, noradrenaline and histamine. In the brains of people with schizophrenia, various 
changes are found in the histaminergic system (Prell et al., 1995, Jin et al., 2009). Levels of t-
MeHA are elevated in the spinal fluid of patients with schizophrenia (Prell et al., 1995), this 
implies that there is increased histamine release and turnover that could explain the low H1-
receptor binding that is observed in the frontal cortex of people with schizophrenia (Nakai et 
al., 1991). Histamine–H3R binding is increased in the dorsolateral prefrontal cortex but 
unchanged in the temporal cortex of patients with schizophrenia compared with those brain 
regions in healthy control subjects (Jin et al., 2009). These differences may reflect the 
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structural abnormalities of the cortical network and changes in cellular composition that 
underlie the functional impairments in this disorder. All antipsychotics act on dopamine D2R, 
supporting the proposition of dopaminergic supersensitivity as a major factor in disease 
susceptibility and pathogenesis (Seeman et al., 2006). H3R antagonist/inverse agonist increase 
the dopamine and acetylcholine levels in the cortex but not in striatum, suggesting that 
negative symptoms and cognitive deficits could be ameliorated. Preclinical and clinical 
studies indicate that H3R antagonist/inverse agonist are not sufficient as antipsychotic therapy 
per se but represent a promising poly-therapy treatment in schizophrenics. Thus, 
antagonist/inverse agonist H3R, D2R, 5-HT2A combination, could be considered a rational 
approach in different types of psychosis treatments (von Coburg et al., 2009, Ito, 2009, 
Tiligada et al., 2009). 
4.  Is histaminergic neurotransmission involved in antidepressant 
responses? 
4.1 Historical background 
The term depression began to appear in the 19th century as did the modern concept of 
affective disorders, with the core disturbance now viewed as one of mood. Melancholia was 
recognized as early as the time of Hippocrates, and continued through galenic medicine and 
medieval times. The earlier connotation of the term was very wide, and included all forms of 
quiet insanity. Melancholia later became more clearly associated with the more modern idea 
of melancholy or despair, for instance, in the classic work of the English Renaissance author, 
Richard Burton, The Anatomy of Melancholy, first published in 1621.  
The first division of the major endogenous psychoses is related to Kraepelinian dichotomy 
that delineates the foundations of the modern classification of psychiatric disorders. This 
division was formally introduced in the sixth edition of Emil Kraepelin's psychiatric 
textbook Psychiatrie. Ein Lehrbuch für Studirende und Aertze, published in 1899 (Decker, 
2007).  Kraepelin regarded psychiatric disorders as disease entities based on a medical, 
neurological model, with specific, organic etiology and pathology.  He did, however, regard 
some pathological depressions as psychogenic in origin. While he did not completely clarify 
his views on their position in his classification, or how they were to be distinguished from 
manic-depressive illness with incidental stress, he appeared to regard them as a separate, but 
relatively small and unimportant group.  
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Another school of European psychiatrists was developing a very different approach. The 
psychoanalysts. Freud and Abraham, developed a theory of the origin of depression in 
relation to actual or symbolic losses of a love object. Here was a theory regarding the origin 
of most, if not all, depressions as psychogenic. Psychological theories of causation became 
more widely accepted for these disorders. A challenge now arose as to how to reconcile these 
theories with older ones of organic causation. Adolf Meyer, a Swiss psychiatrist moved away 
from the idea of clear cut disease entities, and viewed all psychiatric disorders as reaction 
types, or psychobiological reactions of the organism to stress (Meyer, 1922). The Meyerian 
concept defined depression as a type of reaction in which both psychological and organic 
factors had to be taken into account (Paykel, 2008).  
4.2 The modern concept of depression 
Depression is among the leading contributors to the global burden of disease (Whiteford et al., 
2013), globally, more than 300 million people of all ages suffer from depression. It is 
associated with enormous personal suffering and societal economic burden (Kessler et al., 
2003) with 10-30% of women and 7-15% of men likely to suffer from depression in their life-
time (Briley and Moret, 2000). Furthermore, depression can be a lethal illness owing to an 
elevated risk for suicide (Trivedi et al., 2006), as well as increased risks of cardiac disease, 
cerebrovascular disorders and other medical causes of mortality (Walker et al., 2015). The 
magnitude of the clinical burden of depression reflects, in part, the limited effectiveness of 
present-day treatments. Currently available antidepressant medications, alone and in 
combination, are associated with high rates of partial responsiveness or non-responsiveness, 
delayed response onset of weeks to months and limited duration of efficacy (Gaynes et al., 
2012). Despite the high prevalence of depression and its socioeconomic impact, the etiology 
and pathophysiology of this complex disorder is not well understood. It is the lack of 
understanding of the underpinning of depression that has resulted in no substantial 
improvement to antidepressant treatment (Misra, 2012) and consequently the lack of 
improvement over the conventional monoaminergic-based therapies discovered by serendipity 
decades ago (Kessler et al., 2008, Covington et al., 2010).  
A major liability of the monoamine-deficiency hypothesis is its derivation from the 
mechanism of currently available antidepressants. Despite their efficacy, however, current 
antidepressant pharmacotherapy alleviates symptoms in approximately two thirds of patients 
proving a clinical response to these agents, whereas one third have a response to placebo 
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(Mann, 2005). Perhaps the mechanism of depression is not related to monoamines in two of 
three cases (Belmaker and Agam, 2008). Indeed, the monoaminergic theory for depression is 
not able to explain the fact that biochemical effects of antidepressant rapidly occur whereas 
the therapeutic response has a delay of days or weeks (Stahl, 2008). Thus, the immediate 
effects of antidepressant drugs on monoamines cannot fully explain this lag period of 
treatment response (Malberg and Blendy, 2005). 
To better understand mechanisms underlying the therapeutic efficacy of antidepressant drugs, 
research efforts have focused on the long-term molecular changes the underlie depression and 
antidepressant treatments.  
4.3 Neurogenic and neurotrophic theory  
The supposition that monoamine deficits may not reflect a core feature of depression 
pathophysiology, but are the result of neural dysfunction directed research away from 
monoamines and towards the putative role of growth factors such as brain-derived 
neurotrophic factor (BDNF), known to be critically involved in regulating neural structure 
and plasticity in the adult brain (Thoenen, 1995, Kafitz et al., 1999). The first studies to 
implicate BDNF in antidepressant responses showed that conventional antidepressant drugs, 
as well as electroconvulsive therapy (ECT), enhanced BDNF and TrkB mRNA expression in 
the hippocampus and cortical regions in a timeframe similar to the onset of antidepressant-
like response (Nibuya et al., 1996, Nibuya et al., 1995). To more directly examine the causal 
involvement of BDNF in antidepressant responses, Siuciak and colleagues infused BDNF 
protein directly into the midbrain and observed an antidepressant-like effect in rodents 
(Siuciak et al., 1997). 
In humans, acute and chronic stress both decrease endogenous neurotrophin levels and can 
lead to significant atrophy of the hippocampus, a structure known to be involved in 
controlling emotionality (Sapolsky, 1996, McEwen, 2000, Duman, 2004).These events may 
be causally linked via neurogenesis (Duman, 2005). 
Neurotrophins are growth factors with crucial roles in the formation and plasticity of neuronal 
networks (Huang and Reichardt, 2003). The neurotrophin family include nerve growth factor 
(NGF), BDNF, neurotrophin-3 (NT-3) and neurotrophin-4 (NT-4). They are initially 
synthesized as precursor proteins (proneurotrophins), which are processed extracellular or 
intracellularly to be secreted mostly in a mature, biologically active form (Matsumoto et al., 
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2008, Yang et al., 2009). The neurotrophins, show binding specificity for particular tyrosine 
kinase receptors (Trk), and non-specificity for the p75 neurotrophin receptor (p75NTR). In 
particular, pro-BDNF preferentially activates p75NTR receptor to mediate programmed 
neuronal death (Frade et al., 1997), to decrease dendrite complexity and spine density in 
hippocampal neurons (Zagrebelsky et al., 2005), and to induce long-term depression of 
synaptic transmission (Rösch et al., 2005, Woo et al., 2005). On the contrary, mature BDNF 
(mBDNF) selectively activates TrkB, a member of the tyrosine kinase receptors family, to 
promote survival and differentiation, increasing the branching of axons and dendrites and 
stabilizing synaptic contacts (Lee et al., 2001). Thus, due to the essential role of BDNF for 
cell differentiation, nerve growth and neuronal survival it has been implicated in several brain 
diseases, including depression considering its well establishes relation with low levels of 
BDNF expression (Neto et al., 2011).  
Birth of new neurons or neurogenesis continues to occur in selected neurogenic zones in the 
adult brain. This includes the subventricular zone that gives rise to olfactory bulb neurons, 
and the subgranular zone that generates granule cells of the hippocampal dentate gyrus. 
Similar to regulation of BDNF in the dentate gyrus, stress and antidepressant treatments exert 
opposing effects on neurogenesis in the adult hippocampus. Stress and depression decrease 
the expression and function of BDNF in the PFC and hippocampus, structures that are 
implicated in depression, as well as decrease the BDNF levels in the blood of subjects with 
depression (Krishnan and Nestler, 2008, Bocchio-Chiavetto et al., 2010, Turner et al., 2006). 
Reduced neurotrophic or growth factor levels may be particularly relevant to the structural 
alterations caused by stress and depression, as these factors (particularly BDNF) are required 
for activity-dependent formation and maintenance of synaptic connections (Holtmaat and 
Svoboda, 2009, Jourdi et al., 2009). Studies of a human BDNF polymorphism 
(BDNFVal66Met) that is found in approximately 25% of the population have been insightful. 
The presence of the BDNFVal66Met allele, whose product results blocks the processing and 
release of mature BDNF, is sufficient to cause atrophy of neurons in the hippocampus (Chen 
et al., 2006) and medial PFC (mPFC) of mice with this allele (Liu et al., 2012). Heterozygous 
deletion of BDNF also decreases spine density and dendrite length of hippocampal and PFC 
neurons, decreases hippocampal volume and occludes the effects of chronic stress (Liu et al., 
2012, Magariños et al., 2011). These findings suggest that stress could cause neuronal  
atrophy via inhibition of BDNF or that BDNF is required for neuronal remodelling (Duman et 
al., 2016). 
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A different point of view actually discusses the balance between neuronal death and 
neurogenesis as an etiological cause of this pathology (Malberg et al., 2000, Jacobs et al., 
2000). In fact, neurogenesis is a possible phenomenon in adults (Duman et al., 2001, Gould 
and Tanapat, 1999) and neurotrophins are important for nervous cells formation and 
differentiation (Fariñas et al., 2001, Fritzsch, 2003). Several studies have been proposed to 
test some of these theories relating the balance between neuronal death and neurogenesis, but 
most of them still lack experimental verification (Merighi et al., 2008).  
4.4 Role of CREB in Depression and Antidepressant Treatments  
The neurotrophic theory of depression led to a novel therapeutic approach in the management 
of depression beyond manipulation of neurotransmitter-receptor interaction, consisting in 
targeting signal transduction and gene expression pathways. The most investigated pathway, 
in that sense is the Cyclic AMP (cAMP) second messenger system which ultimately influence 
gene expression by activating the transcription factor cAMP response element binding protein 
(CREB).  
CREB is a nuclear protein. It belongs to the family of leucine zipper transcription factors that 
are expressed in a variety of tissues and serve diverse functions. Phosphorylation of a serine 
residue (S133) in its kinase inducible domain is critical to mediate its effect, as this permits 
recruitment of co-activator proteins and initiation of transcription (Nair and Vaidya, 2006). 
Activation of CREB can be accomplished by phosphorylation via cAMP-protein kinase A 
(PKA) pathway. PKA cascade also serves as a target for antidepressant treatment (Figure 3) 
(Tardito et al., 2006). 
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Figure 3. cAMP response element-binding protein/brain-derived neurotrophic factor 
signal transduction pathway (Wang et al., 2013)  
CREB is regulated by diverse signalling pathways and integrates the action of numerous 
external stimuli, including antidepressant. A downstream consequence of enhanced CREB 
function is thought to be the increased expression of target genes like the neurotrophin, brain-
derived neurotrophic factor (BDNF) (Figure 3), and neuropeptide Y (NPY), which may 
contribute to the antidepressant treatment mediated changes in structural plasticity and 
behaviour (Conti et al., 2002, Pandey, 2003). As previously mentioned, the hippocampus is a 
key limbic region whose structure and function is compromised in mood disorders. 
Hippocampal over-expression of CREB and BDNF can mimic both the structural 
consequences of sustained antidepressant treatment as well as exerting antidepressant like 
behaviour (Chen et al., 2001). Elevated CREB-BDNF, through their protective influences on 
vulnerable hippocampal neurons and their ability to directly promote structural recognition, 
could result in repair of damaged region due to depression (Misra, 2012). Elevated CREB 
function can either reduce or produce depressive-like behaviour in laboratory animals. For 
instance, elevated CREB activity in the NAc produces various depressive-like effects in 
rodents (Barrot et al., 2002). Until recently, the NAC has not been considered a likely site for 
the pathophysiology of depression, although it makes intuitive sense that symptoms of 
anhedonia, reduced energy and reduced motivation, which are prominent in many depressed 
patients, involve this brain reward region (Pliakas et al., 2001, Nestler et al., 2002). Within the 
amygdala, the consequences of alterations in CREB function appear to be state-dependent. 
Virus-mediated expression of CREB in the amygdala before training in the learned 
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helplessness paradigm causes depressive-like effect, whereas expression after training results 
in antidepressant-like effect (Wallace et al., 2004). These finding provide further evidence 
that the actions of CREB are regionally and temporally specific. Therefore, the increased 
CREB function within the hippocampus produces antidepressant-like effects that correlate 
with elevated expression of growth factors such as BDNF, whereas the same increases in 
CREB function within the NAc produce many depressive-like signs. Such observations 
highlight the fact that CREB functions generally regulate plasticity, a process that is not good 
or bed; it could be adaptive, maladaptive, or both simultaneously. In the case of depression, 
elevations in CREB activity in one region and reduction in another could detract from the 
therapeutic action of treatment regimens that produce global influences on CREB function in 
the brain (Carlezon et al., 2005).   
4.5 Neurocircuitry of depression 
Regions within the orbital PFC (oPFC) and the mPFC appear to work as a coordinated unit to 
integrate sensory information, provide emotional salience and modulate visceral motor 
reactions and value-based decision processes (Wallis, 2011). These regions have connections 
with several sensory areas (Carmichael and Price, 1995), as well as inputs from the 
hypothalamus, amygdala, NAc and hippocampus. In rodents, the infralimbic PFC (IL-PFC) is 
believed to have roles similar to those of the oPFC-mPFC networks, by integrating 
information and modulating visceral reactions that are related to emotional processes through 
connections with the amygdala, hypothalamus and various brain stem nuclei (Vertes, 2004). 
Recent work suggests that the IL-PFC also modulates activation of the ventral tegmental area 
through effects on the amygdala and ventral subiculum, tying the region to subcortical 
reward-processing networks (Patton et al., 2013). Anhedonia, especially deficits in non-
consummatory reward behaviour, is another core symptom of depression. Abnormal activity 
levels  in the PFC-ACC, as well as in the ventral and dorsal striatum, have been reported in 
depressed patients with anhedonia (Pizzagalli, 2014). 
Depression is also highly heritable, with roughly 40-50% of the risk for depression being 
genetic, although the specific genes that underlie this risk have not yet been identified. The 
remaining 50-60% of the non-genetic risk also remain poorly defined, with suggestion that 
early childhood trauma, emotional stress, physical illness, and even viral infections might be 
involved. Therefore, the highly variable compilation of symptoms that is used to define 
depression, and the highly variable course of the illness and its response to various treatments, 
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indicate that depression subsumes numerous disease states of distinct etiology, and perhaps 
distinct pathophysiology. In fact, the lack of bona fide objective diagnostic test for depression, 
beyond a compilation of symptoms, means that the diagnosis of the syndrome is quite 
variable, with no clear line distinguishing people who have mild clinical depression from 
those who are simply having a tough time in the course of normal life (Berton and Nestler, 
2006). 
4.6 Animal Models used to screen antidepressant compounds 
Despite the prevalence of depression and its serious impacts, studies on the pathogenesis of 
depression are still preliminary compared to those on the pathogenesis of other common 
chronic and potentially fatal multi-factorial conditions (Yang et al., 2010); the major obstacle 
is the restricted availability of validated animal models.  
Ideally, an appropriate animal model of human depression should fulfill the following criteria 
as much as possible: strong phenomenological similarities and similar pathophysiology (face 
validity), comparable etiology (construct validity), and common treatment (predictive 
validity) (Willner and Mitchell, 2002, Vollmayr et al., 2007). Unfortunately, depression is a 
heterogeneous disorder and its many core symptoms (e.g., depressed mood, feeling of 
worthlessness, and recurring thoughts of death or suicide) are hard to be mimicked in 
laboratory animals.  
It should be noted that there is a difference between a model and a test. A model can be 
defined as an organism (non-human) or a particular state of an organism that reproduces 
aspects of human pathology, providing a certain degree of predictive validity. A test, on the 
other hand, provides only an end-point behavioural or physiological measure (read-out) 
designed to assess the effect of a genetic, pharmacological or environmental manipulation  
(Urani et al., 2005). 
While symptoms of depression are likely to be purely human features, other aspects of the 
depressive syndrome have been replicated in laboratory animals, and in several instances 
ameliorated with antidepressant treatment. These include measures of helplessness, 
anhedonia, behavioural despair and other neuro-vegetative changes such as alterations in 
sleep and appetite patterns (Krishnan and Nestler, 2011). Many of the test commonly used to 
detect antidepressant compound are essentially validated retrospectively based on the effects 
seen with clinically effective antidepressant agents, it is perhaps more appropriate to consider 
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them as a test of antidepressant action rather than test of depression (Cryan and Mombereau, 
2004). 
I will mention only the most widely used preclinical tests used to screen antidepressant 
compounds. 
4.6.1 Tail Suspension Test (TST)  
The TST is based on the observation that rodents after initial escape- oriented movements, 
develop an immobile posture when placed in an escapable stressful situation, that in TST 
involves haemodynamic stress of being hung in an uncontrollable fashion by their tail 
(Thierry et al., 1986). If antidepressant treatments are given prior to the test, the subjects will 
actively persist engaging in escape-directed behaviours for longer periods of time than after 
vehicle treatment. The test is usually quite short, 6 minutes, and the amount of time they 
spend immobile is recorded (Steru et al., 1985). Similar to the FST, its validity is questioned 
by the fact that acute antidepressant treatments reverse the behavioural “depression” (Cryan 
and Mombereau, 2004). Although both the FST and TST are similar in the construct that they 
purport to asses they are probably different in term of the biological substrates that underlie 
the observed behaviour although they often offer converging data on potential antidepressant 
(Porsolt, 2000, Bai et al., 2001, Renard et al., 2003).   
4.6.2 Forced Swim Test (FST)  
The Porsolt test (Porsolt et al., 1977), also known as the FST test is the most widely and most 
frequently used experimental paradigm to detecting antidepressant activity, largely due to its 
relative reliability across laboratories and its ability to detect activity in a broad spectrum of 
clinically effective antidepressant (Cryan et al., 2002, Porsolt, 2000). The test is based on the 
observation that rodents, following initial escape-oriented movements, develop an immobile 
posture in an inescapable cylinder filled with water. If antidepressant treatments are given 
prior to the test, the subjects will actively persist engaging in escape-directed behaviours for 
longer periods of time than after vehicle treatment (Cryan and Mombereau, 2004).  
An interpretation of these tests as a model of depression is that immobility time is a symptom 
of reduced reactivity to an aversive environment, and the fact that the administration of an 
antidepressant prolongs the struggling or swimming time should give predictive validity to the 
model. A main criticism of this interpretation is that a very short-term treatment (acute or 
short term 3-4 administration within 24h) is sufficient for shortening immobility time, and this 
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fact conflicts with the delay necessary for an antidepressant compound to develop its 
therapeutic activity. 
There are several differences between the two tests, such as their differential sensitivity to the 
immobility-reducing effect of various antidepressant with an apparent increased sensitivity of 
the TST. The mouse FST has not traditionally been viewed as a consistently sensitive model 
for detecting SSRIs activity (Porsolt and Lenegre, 1992) whereas these antidepressant are 
generally reported as active in the TST (Cryan et al., 2005).  
Despite the major disadvantage of the TST related to its sensitivity to short-term 
antidepressant, the validity of the TST is based on the behavioural responses, comprising an 
evolutionary preserved coping strategy in which immobility behaviour represent the 
psychological concept of “entrapment” described in clinical depression (Dixon et al., 1998, 
Lucki, 2001). It is reasonably analogous to the human disorder in its manifestation or 
symptomatology, there are behavioural changes that can be objectively monitored, the 
behavioural changes observed should be reversed by the same treatment modalities that are 
effective in humans (Cryan et al., 2005). This fact would imply that TST should be considered 
a good model of antidepressant action.   
4.6.3 Chronic Mild Stress (CMS) 
One of the most elegant long-term models of depression is the chronic mild stress procedure 
devised by Willner (Papp et al., 1996, Papp et al., 1991). As the name suggests this paradigm 
consists of exposing rodents to a series of mild unpredictable stressors during a prolonged 
period (usually >2 weeks).  This stress regimen induces many long-term behavioural, 
neurochemical, neuroimmune and neuroendocrine alterations resembling dysfunctions 
observed in depressed patients (Willner, 1997). In the CMS model, chronic sequential 
exposure to a variety of mild stressors has been shown to decrease the drinking of a 
sweetened solution, a condition that could be reversed by the chronic administration of 
classical antidepressant drugs as well as dopaminergic agonists (Willner et al., 1992, Muscat 
et al., 1992, Muscat et al., 1990, Papp et al., 1996). Exposure to chronic mild stress also 
impairs the acquisition of place preference conditioning, in parallel with sucrose consumption 
(Papp et al., 1991). These anhedonia-like behaviours have generally been shown to be 
reversed by chronic, but not acute, treatment with several classes of antidepressants (Willner, 
1997, Moreau et al., 1992). Although the paradigm has been described as a model with a high 
predictive, construct and etiological validity (Willner, 1990, Cryan and Mombereau, 2004). 
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Nevertheless, reservations concerning the reproducibility of the behaviour results obtained 
have been raised, thus questioning the reliability of the model. 
4.6.4 Learned Helplessness 
This paradigm was originally developed based on the observations that dogs subjected to 
repeated inescapable uncontrollable (but not those subjected to controllable) shocks 
demonstrate escape deficits (Overmier and Seligman, 1967, Seligman and Maier, 1967). The 
model was later translated to the rat (Seligman and Beagley, 1975) and subsequently to the 
mouse (Anisman et al., 1979). The rodent studies revealed that the behavioural deficits are 
sensitive to a broad spectrum of antidepressants usually after short-term treatment (Leshner et 
al., 1979, Petty and Sherman, 1979, Martin et al., 1990b, Martin et al., 1990a). The major 
drawbacks of the learned helplessness model are two-fold: first most of the depression-like 
symptomatology does not persist beyond 2–3 days following cessation of the uncontrollable 
shock (Weiss and Kilts, 1998). Further, only a certain percentage (estimates vary somewhere 
between 10 and 80%) of animals develop helplessness behaviour (Drugan et al., 1989). 
4.6.5 Novelty-suppressed feeding and sucrose preference  
Novelty-suppressed feeding (NSF) test is a hyponeophagia-based behavioural test and 
provides an anxiety-related measure that is sensitive to the effects of chronic treatment with 
AD. The NSF also exhibits considerable potential as animal models for studying the 
neurobiology of the AD response (Dulawa and Hen, 2005). The NSF elicits competing 
motivations: the drive to eat and the fear of venturing into the centre of a brightly lit arena. 
Chronic, but not acute treatment with AD could significantly decrease the animal’s latency to 
eat, while it does not affect the food intake of animals in their home cage (Santarelli et al., 
2003).  
The sucrose preference test is usually used for analysing the effect of drugs on depressive 
animals. Reduced preference for sweet solution in sucrose preference test represents a loss of 
interest, fatigue and a loss of energy during depressive episodes, while this reduction can be 
reversed by treatment with ADs. The reduced sucrose preference has been used as a measure 
of anhedonia in the animal models of CMS and learned helplessness (Vollmayr et al., 2004, 
Willner et al., 1987). 
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4.6.6 Neuronal histamine: an insight on depression 
Pharmacological or genetic loss of histamine or histamine receptor function in animals 
produces phenotypes that model human depression (Dai et al., 2007, Ito et al., 1999, Nath et 
al., 1988, Song et al., 1996). Histamine neurons in the TMN are sensitive to many, if not all, 
neuroendocrine signals implicated with depression, including biogenic amines, peptides, and 
steroid hormones, as well as antidepressant medication. Histamine neurons are strongly 
excited through 5-HT2C, a serotonin receptor that undergoes posttranscriptional editing 
(Sergeeva et al., 2007) that correlates with suicide (Schmauss, 2003). Noradrenergic α2-
receptors increase GABAergic inhibition of TMN neurons (Nelson et al., 2003, Stevens et al., 
2004), and interactions with peptidergic influences, e.g., hypocretins (Eriksson et al., 2004, 
Eriksson et al., 2001), CRH, and steroid hormones, may be implicated in neuroendocrine and 
coping abnormalities in depression.  
PET studies using [11C] doxepin, an antidepressant with high affinity to H1R, revealed 
reduced H1R binding in frontal and prefrontal cortices, and the cingulate gyrus correlating 
with the severity of clinical depression (Kano et al., 2004, Yanai and Tashiro, 2007). 
Anomalies in histamine metabolism (methylation) may account for endogenous depression in 
humans (Gagne et al., 1982), and the association of depression and atopy (Timonen et al., 
2003) is in line with convergent roles of histamine in immune and stress responses 
(Theoharides and Konstantinidou, 2007, Steinman, 2004).  
Munari and coworkers (2015) demonstrated that an intact histaminergic neurotransmission is 
essential for the SSRI citalopram and paroxetine to exerts their behavioural and 
neurochemical actions in the TST paradigm. Munari et al., help to clarify also the putative 
interactions between the serotonergic and histaminergic systems in the antidepressant action 
of these two compounds suggesting that SSRIs increase extracellular levels of endogenous 5-
HT in the TMN, which in turn impacts 5-HT2C receptors localized on HA neurons, enhances 
their firing rate, and consequently augments HA release in the cortex. Disruption of this loop 
in HA-deprived mice is at least in part responsible for the inefficacy of citalopram and 
paroxetine (Munari et al., 2015).  
Single nucleotide polymorphism of the HA H1R gene was found to play a role in bipolar 
disorder, as it was significantly associated with improvements following olanzapine and 
fluoxetine treatment (Perlis et al., 2010). In addition, functional mutation in the HDC gene 
resulting in deficits of the histaminergic neuronal system has been linked to the mechanism 
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and modulation of Tourette’s syndrome and tics (Ercan-Sencicek et al., 2010, Baldan et al., 
2014). Similar genetic variations in the population may contribute to individual differences in 
antidepressant response and may prove good predictors of more effective treatments (Munari 
et al., 2015). Modulation of histaminergic system may thus prove to be useful in the 
treatments of depression and related mood disorders.  
5. Is neuronal histamine involved in stress-related responses?  
5.1 Historical Background 
Aristotle, Hippocrates, and the other Ancients were aware of stress and its adverse effects. 
However, Claude Bernard was the first to formally explain how cells and tissues in 
multicelled organisms might be protected from stress. Bernard, first pointed out (1859) that 
the internal medium of the living organism is not merely a vehicle for carrying nourishment to 
cells. Rather, is the condition of life. Fifty years later, Cannon, working at Harvard, suggested 
the designation homeostasis for the coordinated physiological processes that maintain most of 
the steady states in the organism. Cannon coined the term 'fight or flight' to describe an 
animal’s response to threat. The concept of 'fight or flight' proposes that animals react to 
threats with a general discharge of the sympathetic nervous system, priming the animal for 
fighting or fleeing. This response was later recognized as the first stage (acute stress response) 
of a general adaptation syndrome (GAS) postulated by Hans Selye to be a universal stress 
response among vertebrates and other organisms. Selye, also known as the “father of stress”, 
observed that patients with a variety of illnesses had many of the same “nonspecific” 
symptoms that were a common response to stressful stimuli experienced by the body. These 
clinical observations together with experiments on laboratory rats underpinned Selye’s 
concept of GAS, which led Selye to assert that prolonged exposure to stress resulted in 
“diseases of adaptation”. That is, chronic stress, by causing the overproduction of chemicals 
and hormones, produced gastroduodenal ulcers and high blood pressure. Although the GAS 
hypothesis was subsequently shown to be incorrect, it did put stress on the map and also 
highlighted the fact that stress had major effects on the immune system as well as on the 
adrenal glands. In addition to providing the first clear definition of stress, Hans Selye was also 
the first to recognize that homeostasis could not by itself ensure stability of body systems 
under stress. A different tack, focused on cognition, was taken by Lazarus, the eminent and 
influential Berkeley University psychologist. At a time when psychology tried to understand 
human behaviour by first understanding simple organisms engaging in simple behaviours 
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learned by associations, rewards, or punishments, Lazarus instead emphasized the importance 
of studying cognition, which he extended into stress and coping. In parallel with these stress 
concepts, during the years, neuroendocrine advances revealed the physiological substrate for 
homeostasis, allostasis, and the stress response mechanisms. The autonomic nervous and the 
hypothalamic–pituitary–adrenocortical (HPA) systems affect the afferent and efferent limbs 
of the stress response in vertebrates and are also central to maintaining homeostasis and 
effecting allostasis (Fink, 2009). 
5.2 Definition and Classification of Stress 
The term “stress”, as it is currently used was coined by Selye in 1936, who defined it as “the 
non-specific response of the body to any demand for change”.  Threats to well-being, whether 
physical or psychological, are components of life experience. Individuals differ markedly, 
however, in the frequency with which they experience stressful life events and their 
vulnerability or resilience to stressful challenges (Herman et al., 1995). Stress, although often 
studied as a psychological construct, may be viewed from a biological perspective (Dantzer, 
1991). Accordingly, stress responses are composed of the activation of neurobiological 
systems that help preserve viability through change or allostasis (McEwen and Seeman, 
1999). Although necessary for survival, the effects of frequent physiological stress responses 
may increase the risk of future physical and mental health problems (Gunnar and Quevedo, 
2007).  
The Diagnostic and Statistical Manual of Mental Disorders (DSM-V) recognizes two stress 
disorders: acute stress disorder and posttraumatic stress disorder (PTSD). For the diagnosis of 
acute stress disorder, the individual, while experiencing the trauma or after the event, must 
have at least three of several dissociative symptoms, such as a subjective sense of numbing, 
detachment, or absence of emotional responsiveness; reduction in awareness of surroundings; 
depersonalization; or dissociative amnesia. Following the trauma, the traumatic event is 
persistently re-experienced, the individual avoids stimuli that may arouse recollections of the 
traumatic event, and they have anxiety or increased arousal. PTSD is defined as a condition in 
which a traumatic event is persistently re-experienced in the form of intrusive recollections, 
dreams, or dissociative flashback episodes. Cues to the event lead to distress and are avoided, 
and there are symptoms of increased arousal; the full symptom picture must be present for 
more than one month, and the disturbance must cause clinically significant distress or 
impairment in social, occupational, or other areas of functioning (Fink, 2009).  
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5.3 Neuroanatomy and Physiology of Stress 
Stress responses in mammals are affected by two distinct, but interrelated systems: the 
sympathetic-adrenomedullary (SAM) (Frankenhaeuser et al., 1986) system and the 
hypothalamic-pituitary-adrenocortical (HPA) (Stratakis and Chrousos, 1995) system. The 
SAM system is a component of the sympathetic division of the autonomic nervous system, 
releasing epinephrine (adrenaline) from the medulla or centre of the adrenal gland. Increases 
in circulating epinephrine facilitate rapid mobilization of metabolic resources and 
orchestration of the fight/flight response (Jansen et al., 1995). The HPA system, in contrast, 
produces glucocorticoids (cortisol in humans, corticosterone in rodents; hereafter GCs) which 
are steroid hormones. Unlike epinephrine, which does not cross the blood-brain barrier to a 
significant degree, the brain is a major target of GCs (Bohus et al., 1982). Also unlike 
epinephrine, GCs production takes some time (approximately 25 minutes to peak levels), and 
many of its impacts on the body and brain occur through the changes in gene expression (de 
Kloet et al., 1991). Consequently, the impacts of GCs are slower to develop and continue for 
longer periods (De Kloet et al., 1996). The role of the HPA system in stress is complex, and 
its functions are not fully captured by reference to the fight/flight response (Sapolsky, 2000). 
Regulation of both the SAM and HPA systems converges at the level of the hypothalamus, 
which integrates autonomic and endocrine functions with behaviour (Palkovits, 1987). 
Furthermore, inputs to the hypothalamic nuclei that orchestrate HPA and SAM responses to 
psychosocial stressors involve cortico-limbic pathways (Gray and Bingaman, 1996). 
5.4 Stress: social behaviour, and resilience 
Social stress, a common stressor readily translated across species, is a recurrent factor in the 
life of all social species (von Holst, 1998). The effects of stress exposure and consequent 
trajectory depend on the nature of the stressor, the severity, duration (acute vs. chronic), 
sex/gender, genetics, timing of exposure (early life, adolescence, adulthood or aging) as well 
as the perception of the stressor by the individual, for example, stressor controllability 
dramatically affects resilience versus vulnerability as an outcome (Maier and Watkins, 2005, 
Amat et al., 2010, Lucas et al., 2014). There are three main categories of social stressors. Life 
events are defined as abrupt, severe life changes that require an individual to adapt 
quickly. Chronic stressors are defined as persistent events which require an individual to 
make adaptations over an extended period of time. When stress becomes chronic, one 
experiences emotional, behavioural, and physiological changes that can put one under greater 
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risk for developing a mental disorder and physical illness. Understanding the mechanisms 
underlying stress-induced disturbances will ultimately allow for improved clinical therapies 
and possible preventative strategies to decrease the incidence of these disorders. 
Resilience refers to a person's ability to adapt successfully to acute stress, trauma or more 
chronic forms of adversity. A resilient individual has thus been tested by adversity (Rutter, 
2006) and continues to demonstrate adaptive psychological and physiological stress 
responses, or “psychobiological allostasis” (McEwen, 2003, Charney, 2004). Resilience has 
been linked to being able to perceive stressful events in less threatening ways, promoting 
adaptive coping strategies; such cognitive reappraisal allows individuals to re-evaluate or 
reframe adverse experiences in a more positive light (Southwick et al., 2005, Feder et al., 
2009). 
Although many of the above psychological characteristics cannot be measured in animals, 
some behavioural traits associated with resilience have been identified. In numerous animal 
models, rodents display a range of responses to stress: at one extreme are active or “fight-
flight” responses (for example, attempts to escape and aggression), and at the other extreme 
are passive responses (for example, freezing and submission). Active-coping animals are 
often considered to be resilient, based on numerous functional end points, whereas their more 
passive counterparts are not; however, both types of responses can be seen as adaptive 
depending on the particular context (Korte et al., 2005).  
In rodents, acute stress typically leads to reduced social behaviours and increased aggression, 
including antisocial behaviours such as bite counts that exceed species-typical levels (De 
Almeida et al., 2002, Takahashi et al., 2012). This fits with the concept of acute stress as a 
'flight or fight' response and implies that brief acute stressors mobilize resources to cope with 
the situation (Sandi and Haller, 2015). Chronic stress reduces social motivation and social 
interactions in a variety of sociability tests (van der Kooij et al., 2014, Wood et al., 2003).  
However, although chronic stressors generally reduce sociability, social isolation stress 
actually enhances social interest (Van den Berg et al., 1999), probably because long-term 
deprivation from social contacts increases interest in social partners. Aggressiveness is 
increased by chronic physical stressors including chronic unpredictable mild stress (Mineur et 
al., 2003), restraint or immobilization (van der Kooij et al., 2014, Wood et al., 2003, Yohe et 
al., 2012). By contrast, chronic social stressors that involve fighting that leads to defeat and 
subordination have been shown to downregulate aggressiveness in various 
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species. Conversely, repeated victories — which are accompanied by reduced physiological 
stress responses, but which can be considered stressful because they involve recurrent 
exposure to social conflicts — may result in exacerbated and abnormal aggression (Nephew 
and Bridges, 2011, Miczek et al., 2013).  
Stress models that cover a range of neurodevelopmental periods have been applied to 
investigate the long-term impact of stress on adult social behaviours. Social motivation 
(sociability) was disrupted in adulthood by prenatal (de Souza et al., 2013), neonatal (Franklin 
et al., 2011, Yu et al., 2013) and juvenile (Naert et al., 2011, Vidal et al., 2011, Márquez et al., 
2013) exposure to stressors. Prenatal stress (de Souza et al., 2013), neonatal stressors -
maternal separation (Wei et al., 2013) and early deprivation (Jia et al., 2009) - and 
peripubertal exposure to physical stressors (Márquez et al., 2013) inhibited social interactions 
in adulthood. Juvenile social stressors (post-weaning social isolation) (Workman et al., 2011) 
and early subjugation (Wommack et al., 2004) either did not affect this aspect of social 
behaviour or, in one study (Shimozuru et al., 2008), increased adult social interactions. Early 
life stressors decrease measures of social motivation, reduce the expression of social 
behaviours, increase aggressiveness and promote the development of antisocial features, but 
the specific consequences depend on the timing and type of the early stressor. Although these 
changes can be problematic for human individuals and societies, from an evolutionary 
perspective they may be interpreted as mechanisms through which early adversity prepares 
the organism to endure similar adversities later in life (Gluckman et al., 2007). 
5.5 Stress impact on memory function 
Stress is a potent modulator of cognitive function in general, and more precisely, of learning 
and memory processes (McEwen and Sapolsky, 1995, de Kloet et al., 1999, Sandi, 2004). 
Stress effects are frequently regarded as deleterious to cognitive function; but there are many 
instances in which neural function and cognition are either facilitated by stress (de Kloet et 
al., 1999, Joëls et al., 2006), or even not affected (Warren et al., 1991, Beylin and Shors, 
1998). This great variability can be explained by the “intensity” of the stressor (Cordero et al., 
1998) or internal hormonal reactions (Baldi and Bucherelli, 2005, Conrad, 2005, Joëls, 2006). 
Another important factor is stress “duration,” with distinct effects frequently induced by 
single versus repetitive stress or stress hormones activation, and not only at the cognitive 
level, but also when evaluating brain structure and function (Sandi and Loscertales, 1999, 
Pinnock and Herbert, 2001, Pecoraro et al., 2005). Also, important to empathize is the 
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memory phase at which stress acts: consolidation is generally facilitated and retrieval 
generally impaired under stress conditions (Roozendaal, 2003, Roozendaal, 2002). 
Psychological factors, notably stressor controllability and predictability that are well known to 
be key mediators of the psychophysiological impact of stress (Mineka, 1985, Das et al., 2005) 
have also to be mentioned addressing the variability of stress on memory processes. 
Convergent evidence indicates that experiencing uncontrollable stress has deleterious effects 
on further information processing (Maier and Watkins, 2005). To clarify the outcome of stress 
in memory function is important to take into account the existence of individual differences, 
with gender appearing as a strong modulator of such interactions (Luine, 2002, Bowman et 
al., 2003, Shors, 2004). Certainly relevant to understand how stress affects cognition is the 
relevance of the context in which stress is experienced, that is, whether stress is or not 
contingent to the particular information processing under study (Sandi, 1998, de Kloet et al., 
1999, Joëls et al., 2006). 
Chronic stress was also proposed to compromise the hippocampus, a well-known region in 
the brain important for memory processing (Eichenbaum, 1997, O'Keefe, 1978   ). In the 
hippocampus, chronically activating the stress response can produce maladaptive changes, 
which have been postulated to contribute to disease (de Kloet et al., 2005, McEwen and 
Wingfield, 2003, Smith, 1996). A transition into maladaptive changes includes dendritic 
remodelling resulting in reduces dendritic arbors in CA3 neurons; dendritic retraction has 
been observed in other brain regions following ten to 21 days of repeated stress. When 
chronic stress continues for 4 weeks, CA1 and dentate gyrus neurons express dendritic 
retraction (Sousa et al., 2000). Prefrontal cortical neurons also express dendritic retraction 
following 1 to 3 weeks of stress (Brown et al., 2005, Radley et al., 2004). Chronic stress-
induced CA3 dendritic remodelling has been proposed to be a maladaptive response because 
it is associated with susceptibility to damage and cognitive dysfunction (McEwen, 2016). 
Although the majority of studies on chronic stress have focused on structural changes within 
the hippocampus, chronic stress has opposite effects in the basolateral nucleus of the 
amygdala (BLA), where it increases the dendritic complexity of neurons (Vyas et al., 2004, 
Vyas et al., 2002), suggesting that chronic stress facilitates memory under emotionally 
arousing situations.  
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5.6 Chronic Stress Paradigm in rodents 
Different animal models have been developed that use chronic stress to induce 
neuroendocrine and central nervous changes that might reflect also behavioural changes in 
rodents. The chronic stress paradigms are considered to have a greater etiological relevance 
and face validity in mimicking depression, anxiety and other diseases.  
5.6.1 Chronic Social Defeat Stress 
Social stressors have proven to be potent across a wide range of species. Social behaviour is 
complex and varies with the behavioural test chosen, and whether focal individuals are tested 
with familiar or novel conspecifics, with same- or opposite-sex individuals, or with familiar or 
unfamiliar strains. Widely used models of social stress in rodents include social 
subordination, crowding, isolation, and social instability (Figure 4).  
 
 
Figure 4. Schematic representation of the levels at which the social environment impacts 
and reflects the individual (Beery and Kaufer, 2015).  
Social rejection is used as a potent experimental stressor (Kirschbaum et al., 1993), because 
individual's position in the social hierarchy has profound implications for health and well-
being (Adler et al., 1994, Sapolsky, 2005). The social defeat test procedure involves the daily 
exposure to a novel, physically superior aggressor for a defined period of time and results in 
significantly reduced display of social interaction and increased anxiety-like behaviour of the 
defeated animal (van Bokhoven, 2011). Dominance maybe assured by size, prior history of 
winning, strain of the resident, and/or prior housing differences (Martinez et al., 1998). Social 
defeat is typically used as a stressor in male rodents, for whom dominance is easier to 
quantify and aggressive interactions related to home territory are presumed more salient 
(Beery and Kaufer, 2015). In the short-term, social defeat produces changes in heart rate, 
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hormone secretion, and body temperature, with longer-term impacts on a wide variety of 
additional outcomes including activity, social behaviour, drug preference, disease 
susceptibility and others (Martinez et al., 1998, Sgoifo et al., 1999, Peters et al., 2012). Social 
defeat stress has profound effects on hippocampal morphology and function (McEwen, 2012, 
McEwen and Magarinos, 2001, Buwalda et al., 2005, Mirescu and Gould, 2006). These 
effects include reduction in hippocampal volume (Czéh et al., 2001) related to dendritic 
remodelling and reduced neurogenesis (Magariños et al., 1996, Gould et al., 1998). After 
prolonged exposure to social defeat stress (and stressful conditions in general), animals often 
show an altered brain structure and cognition (McEwen, 1999, Sandi and Pinelo-Nava, 2007), 
that is said to increase the risk of developing neuropsychiatric disorders (de Kloet et al., 2005, 
Nemeroff et al., 2006)).  At the molecular level, BDNF has been reported to play an important 
role in social defeat stress (Berton and Nestler, 2006). As the key downstream regulatory 
factor, CREB is a constitutively expressed regulatory nuclear transcription factor involved in 
not only stress, but also individual development and synaptic plasticity (Guzowski and 
McGaugh, 1997, Sakamoto et al., 2011). 
Social defeat is considered to be one of the most robust animal models of stress-induced 
mood-related illnesses (Berton and Nestler, 2006). Compared to other animal models, the 
social defeat paradigm has higher face, predictive, and ethological validity, which results in 
enduring behavioural and neurobiological changes that mimic several symptoms of the human 
condition (Iñiguez et al., 2014).  
5.6.2 Crowding and Isolation 
Housing density affects rodent behaviour, and both crowded and isolated social environments 
have been used as stressors in rodents. Crowding is a naturalistic stressor especially for social 
or gregarious species that relates to high population density and resource competition in the 
field. In house mice, several studies have shown that crowding can impair reproductive 
function and may be part of population size regulation (CHRISTIAN and LEMUNYAN, 
1958, Christian, 1971). Increased group size is associated with greater dispersal consistent 
with a “social competition” hypothesis (Quirici et al., 2011). Social crowding has been shown 
to impact many different physiological outcomes in rodents. These include changes in organ 
weights, hormone secretion, HPA reactivity, pain sensitivity, telomere length, and cardiac 
outcomes (Gamallo et al., 1986, Gadek-Michalska, 2003, Kotrschal et al., 2007, Grippo et al., 
2011, Tramullas et al., 2012, Puzserova et al., 2013). At the opposite extreme, solitary 
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housing can be a potent stressor for social species. Solitary housing produces an “isolation 
syndrome” particularly in females, consisting of hyperadrenocorticism, reduced body weight, 
altered blood composition, and enhanced pain responsiveness among other outcomes (Hatch 
et al., 1965, Valzelli, 1973). These changes coincide with alterations in behaviour including 
aggression, mating behaviour, learning, and pain sensitivity (Valzelli, 1973). 
5.6.3 Social Instability 
Some studies employ both crowding and isolation in alternation as a model for chronic social 
instability (Haller et al., 1999, Herzog et al., 2009).  In the social instability stress paradigm, 
uncontrollability is modelled by alternating isolation and crowding phases and by the rotation 
of animals among social groups during the crowding phase (Herzog et al., 2009). Social 
instability has particularly been used as a social stressor for female rats, for whom crowding 
and social defeat are not always effective stressors (Palanza et al., 2001). In the crowding 
phase, different social groups consisting of different numbers of males and females are 
formed. Females exposed to this variable social environment show increased adrenal weight, 
increased corticosterone secretion, decreased thymus weight, and reduced weight gain relative 
to females housed in stable male e female pairs (Haller et al., 1999). Social instability also 
induced dysregulation of the hypothalamic-pituitary-gonadal (HPG) axis and reduced sucrose 
preference and food intake (Herzog et al., 2009).  
5.6.4 Chronic Restrain Stress 
Chronic restrain is induced by placing rodents into a well ventilated transparent tube for a few 
hours per day for 2-3 weeks. The animals display depressive-like behaviour (Haenisch et al., 
2009) and also impairment of hippocampal neurogenesis, down-regulation of neurotrophins, 
such as BDNF, and alteration in synaptic plasticity markers (Veena et al., 2009, Pollak et al., 
2010). However, daily exposure to the same kind of stressor at the same time is experienced 
as predictable mild stress, which may actually improve mood and enhance hippocampal 
neurogenesis in mice (Parihar et al., 2011) so that the relevance of this paradigm is 
questionable if not associated with other stressors. 
5.7 Neuronal histamine: an insight on stress  
Histamine release is a sensitive indicator of stress (Taylor and Snyder, 1971, Verdière et al., 
1977), and chronic restraint and/or metabolic stress are among the most potent activators of 
histamine neurons in the TMN (Miklós and Kovács, 2003). Distinct subgroups (E4-E5) of 
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hypothalamic histamine neurons respond to immobility, foot shock, hypoglycemia, and 
dehydration, suggesting a functional heterogeneity of histaminergic TMN neurons (Miklós 
and Kovács, 2003). TMN neurons are influenced by a number of neuroendocrine signals 
(Gotoh et al., 2005) and may integrate exteroceptive and interoceptive state cues in the control 
of stress-induced arousal. Histamine mediates the stress-induced neuroendocrine hormone 
surges of ACTH, β-endorphin, and AVP from the pituitary (Kjaer et al., 1992) and controls 
stress-related activity of aminergic systems, including serotonin-, norepinephrine-, dopamine-, 
and acetylcholine-containing neurons. As an integral part of the neural networks generating 
autonomic patterns histamine neurons interfere with AVP- and CRH-positive sympathetic 
command neurons (Krout et al., 2003) in the PVN and LHA (Whitcup et al., 2004)  to 
influence sympatho-adrenal outflow, cardiovascular functions, and complex stress-related 
behaviours such as 'flight or fight' or grooming. Histamine injections in the PVN activate the 
HPA axis through CRH release. Moreover, both histamine and CRH are released from mast 
cells in the leptomininges and along brain capillaries during systemic stress emphasizing the 
intricate interaction between histamine and CRH, and the nervous and immune system 
(Esposito et al., 2002). 
 
6. Histamine and the gut-brain axis 
The bidirectional signalling between the gastrointestinal tract and the brain is vital for 
maintaining homeostasis and is regulated at the neural (both central and enteric nervous 
systems), hormonal and immunological levels. Perturbation of these systems results in 
alterations in the stress-response and overall behaviour (Rhee et al., 2009). The high co-
morbidity between stress-related psychiatric symptoms such as anxiety with gastrointestinal 
disorders including irritable bowel disorder (IBS) and inflammatory bowel disorder (IBD) 
(Mawdsley and Rampton, 2006, Cámara et al., 2009) are further evidence of the importance 
of this axis. However, increasing evidence also suggests that the enteric microbiome greatly 
impacts on gut-brain communication (Cryan and O'Mahony, 2011). The necessary 
communication processes are based on neurotransmitters, neuropeptides, cytokines, 
hormones, growth factors (among others), which mediate the relationship between the 
immune system and the CNS (Downing and Miyan, 2000). Also, luminal probiotic bacteria 
may alter behaviour and brain biochemistry in a variety of ways even in the absence of 
changes in the inflammatory status of the host (Bercik, 2011). Bacterial products could enter 
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the circulation to pass the blood-brain barrier if they are sufficiently small and lipophilic, or 
they might enter the brain at the circumventricular organs where the barrier is diminished. 
Since prior vagotomy abolishes behavioural and brain biochemical changes induced by 
certain probiotic bacteria (Bravo et al., 2011, Bercik et al., 2011), afferent vagal signalling is a 
necessary condition for the central effects of these neuroactive microorganisms.  
Under stress conditions, the brain may influence the composition of the gut microbiota 
(Bailey and Coe, 1999) via the hypothalamus–pituitary–adrenal (HPA) axis, which regulates 
cortisol secretion, affecting immune cells activity both locally in the gut and systemically. 
Stress can affect such equilibrium (Glaser and Kiecolt-Glaser, 2005), leading to allergic 
reactions, inflammatory responses and predisposition to infection. In turn, gut microbiota, and 
probiotic agents can alter the levels of circulating cytokines, which in turn can have a marked 
effect on several brain functions (Duerkop et al., 2009, Forsythe and Bienenstock, 2010).  
 
Figure 5. Microbiota–gut–brain (MGB) axis. Direct and indirect pathways support the 
bidirectional interactions between the gut microbiota and the central nervous system 
(CNS); involving endocrine, immune and neural pathways  (Montiel-Castro et al., 2013).  
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Recent advances in understanding the molecular and systems biology of the gut-brain axis 
have suggested novel candidates such as gut lipid sensors, and have revealed novel roles for 
lipid sensing in the control of nutrient availability (Schwartz, 2011) and in cognitive 
functions. One of these sensors is the endocannabinoid oleoylethanolamide.  
6.1 Oleoylethanolamide 
The ability to monitor the nutrient composition of food allows animals to generate neural and 
endocrine feedback signals that adapt behaviour and metabolism to environmental 
fluctuations in food availability. Being able to sense dietary fat is especially important, from 
an adaptive perspective, because of the high energy density of this nutrient and the essential 
role of lipids as building blocks of cell membranes and precursors for hormones and other 
bioactive molecules. The need to secure appropriate amounts of fat and optimize its storage 
and utilization provides a plausible evolutionary basis for the existence of multiple lipid-
sensing mechanisms throughout the mammalian body (Piomelli, 2013).  New evidence 
suggests an important role for a different class of signalling molecules – the amides of fatty 
acids (FAs) with ethanolamine (fatty acid ethanolamides, FAEs). The FAEs were first isolated 
from plant and animal tissues more than 50 years ago (Kuehl, 1957, BACHUR et al., 1965) 
and were found to possess strong anti-inflammatory activity (Lambert et al., 2002). The 
discovery of anandamide (AEA), a polyunsaturated FAE led to uncovering the function 
served by FAE family molecules as regulators of food intake (Rodríguez de Fonseca et al., 
2001). This family includes the monounsaturated analogue oleoylethanolamide (OEA) 
(Piomelli, 2013), which, although sharing similar biosynthetic pathways (Okamoto et al., 
2007) with AEA, exerts opposite effects on feeding regulation and lipid metabolism (Romano 
et al., 2014).  
A calcium-dependent N-acyltransferase activity (NAT) catalyses the transfer of a fatty acyl 
group from the sn-1 position of phosphatidylcholine to the amine group of 
phosphatidylethanolamines, producing a family of N-acylphosphatidylethanolamine (NAPE) 
species. NAPEs containing oleic acid at the amine position generate OEA upon hydrolysis of 
their distal phosphodiester bond. This reaction is catalysed by a NAPE-selective 
phospholipase D (NAPE-PLD), which produces phosphatidic acid (PA) as a by-product 
(Figure 6). OEA is hydrolysed into oleic acid and ethanolamine by either of two structurally 
unrelated enzymes: FA amide hydrolase (FAAH) or N-acylethanolamine acid amidase 
(NAAA) (Piomelli, 2013).  
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FIGURE 6.  Biochemical pathway responsible for the production of OEA (Fu et al., 
2011)  
In particular, OEA is synthesized in the upper part of the small intestine, upon the absorption 
of lipids from the diet (Fu et al., 2007, Li et al., 2015). Endogenous OEA itself is nutritionally 
regulated specifically by intestinal lipid administration. Food deprivation reduces OEA 
biosynthesis in the small intestine, while intestinal lipid infusions, but not equicaloric 
carbohydrate or protein infusions, increase proximal small intestinal OEA levels (Schwartz et 
al., 2008). Interestingly, the biosynthetic pathway responsible for lipid stimulated endogenous 
OEA production also generates intra-intestinal oleic acid, bringing full circle an extrinsic 
food-derived lipid signal to a de novo intra-intestinal oleate signal (Schwartz et al., 2008). 
Feeding suppressive effects of small intestinal lipid infusions are mediated in part by a local 
regulatory network within upper small intestine: nutritional lipid is translocated into the 
luminal tissue and stimulates gut OEA and oleic acid biosynthesis (Schwartz, 2011).  
Peripheral OEA administration reduces food intake by increasing the latency to feed and by 
prolonging the interval between two successive meals (Rodríguez de Fonseca et al., 2001, Fu 
et al., 2005, Gaetani et al., 2003). OEA hypophagic actions cannot be attributed to stress or 
malaise because OEA does not produce behaviours that are indicative of fear or anxiety, does 
not change plasma corticosterone levels, and does not induce conditioned taste aversion in 
rats (Proulx et al., 2005, Fu et al., 2005) . The hypophagic actions of OEA depend on the 
feeding state of the animal. In free-feeding rats, OEA decreases meal frequency without 
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altering meal size; by contrast, the compound simultaneously reduces these two parameters in 
food-deprived animals (Gaetani et al., 2003).  
The effects of OEA on food intake appear to be mediated in part by Peroxisome Proliferator 
Activated Receptor (PPAR)-alpha, a nuclear receptor that is also implicated in the mechanism 
that allows liver cells to gauge the levels of circulating FAs (Pawar and Jump, 2003) . OEA 
fails to suppress feeding in PPAR-alpha deficient mice, while PPAR-alpha agonists mimic the 
feeding inhibitory effects of exogenous OEA administration (Rodríguez de Fonseca et al., 
2001). Gut vagal afferents also contribute to the ability of OEA to reduce feeding, as vagal 
capsaicin application blocks OEA induced satiety (Rodríguez de Fonseca et al., 2001). 
Consistent with this finding, OEA also rapidly depolarizes capsaicin-sensitive cell bodies of 
vagal afferent neurons in the nodose ganglion. This activation is likely mediated by the 
transient receptor potential vanilloid type 1 (TRPV1) receptor, as it is blocked by TRPV1 
antagonists and is absent in TRPV1 null mice (Wang et al., 2005). OEA also acts as an 
agonist for GPR119 (Suardíaz et al., 2007), a G protein-coupled receptor that recognizes a 
broad panel of lipid molecules in addition to OEA (Hansen et al., 2012). GPR119 is expressed 
in intestinal endocrine L-cells, which secrete glucagon-like peptide-1 (GLP-1), and 
intraluminal infusions of OEA were found to increase circulating GLP-1 levels in rats 
(Lauffer et al., 2009). Nevertheless, the observation that genetic deletion of TRPV1 or 
GPR119 in mice does not alter the anorexic effects of OEA strongly argues against a direct 
involvement of these receptors in OEA-induced satiety (Lo Verme et al., 2005, Lan et al., 
2009).  
Intraperitoneal injections of OEA stimulate transcription of c-Fos in the Nucleus of the 
Solitary Tract (NST) and in peptide-secreting neurons of the paraventricular (PVN) and 
supraoptic (SON) nuclei of the hypothalamus (Rodríguez de Fonseca et al., 2001, Gaetani et 
al., 2010) and increase the expression of the neuropeptide oxytocin, but not vasopressin. 
Moreover, pharmacological blockade of central oxytocin receptors abrogates the hypophagic 
effects of OEA, implying that release of oxytocin in the hypothalamus and/or other regions of 
the brain may be a key effector of OEA-induced satiety (Gaetani et al., 2010).  
OEA recruits other neurotransmitter systems in the brain to reduce food intake. Recently in 
our laboratory it was shown that histamine deficiency significantly attenuates OEA-induced 
hypophagia (Provensi et al., 2014). As previously reported in this thesis, brain histamine 
affects feeding behaviour, it is fundamental for appetitive and aversive responses during 
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motivated behaviour, and blockade of histamine H1R in the hypothalamus is believed to be 
responsible for the weight gain and metabolic dysregulation associated with the clinical use of 
atypical antipsychotics (Kim et al., 2007).  Provensi and co-workers (2014) demonstrated that 
lack of central histamine dampens OEA-induced increase of c-Fos expression in oxytocin 
PVN neurons. Therefore, OEA requires the integrity of the brain histamine system to fully 
exert its hypophagic effect and the finding establish new functional connections between 
peripherally acting hypophagic signals and brain histamine neurotransmission (Provensi et al., 
2014). 
OEA exert also other functions mediated at least in part by the intestine-brain connections. By 
using the inhibitory avoidance and the Morris water maze test, Campolongo et al. (2009) 
found that i.p. administration of OEA after behavioural training strongly improved the 
retention of these tasks. This effect was blocked by infusions of the local anaesthetic lidocaine 
into the NST or the β-adrenergic antagonist propranolol into the BLA, indicating that the 
signal launched by peripheral OEA gains access to the CNS and strengthens memory 
consolidation by stimulating noradrenergic activity in the BLA (Campolongo et al., 2009). 
This suggest that OEA signalling initiates an integrated response in which satiety induced by 
a fat-rich meal coincides temporally with enhanced encoding of information about the spatial 
and emotional context in which the meal was consumed highlighting the importance of 
metabolic peripherally acting signals in the regulation of higher brain function (Berthoud and 
Morrison, 2008). 
Other behavioural effects of OEA include antidyskinetic effect as assessed by using a 
hemiparkinsonian model of PD in mice with 6-OHDA striatal lesion. OEA treatment reduced 
axial, forelimb and orolingual dyskinetic symptoms, as well as contralateral rotations induced 
by 6-OHDA (González-Aparicio and Moratalla, 2014). Also, OEA reduced spontaneous 
locomotor activity and attenuated psychomotor activation induced by cocaine, an effect that 
does not seem to be mediated by PPARα receptor (Bilbao et al., 2013).  OEA’s central effects 
were also tested in depressive-like behaviour by using two animal models: the chronic 
unpredictable mild stress (CUMS) and tail suspension/forced swim tests. OEA treatment 
normalized sucrose preferences, rearing frequencies, prefrontal cortex and hippocampal 
atrophy and reversed the abnormalities of BDNF and MDA levels and SOD activities in the 
hippocampus and prefrontal cortex, as well as changes in serum levels of ACTH, CORT, and 
T-AOC in CUMS, demonstrating antioxidant properties and normalization of the 
hyperactivity in the hypothalamic–pituitary–adrenal axis (HPA) (Jin et al., 2015). In the 
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TST/FST, OEA treatment decreased the immobility time demonstrating an antidepressant-like 
effect and also and increased cerebral levels of NE and 5-HT regulating central monoamine 
neurotransmitters (Yu et al., 2015a).  
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Aim of the study 
The main scope of my study is to understand the role of the histaminergic system in the 
homeostatic and behavioural effects of oleoylethanolamide (OEA), a fat sensing hormone 
normally secreted by enterocytes in the jejunum. Our working hypothesis is that brain 
histamine serves as a relay station that elaborates peripheral and central signals to allocate the 
relevance and adequate arousal to perform the appropriate behaviour.  
For the purpose of clarity, the manuscript is divided in three parts concerning different aspects 
of the interaction of the histaminergic system and OEA. 
In the first part of the work we demonstrate that brain histamine is necessary for OEA to exert 
its effects on emotional memory. The results appear in the publication Provensi et al., 2017 
(Provensi et al., 2017) that I co-authored. 
In the second part, I investigated whether histamine has a role in OEA’s antidepressant-like 
effects. In this regard, our research group recently demonstrated that selective serotonin 
reuptake inhibitors require the integrity of the brain histamine system to exert their preclinical 
responses (Munari et al., 2015), Consequently we hypothesised a possible relationship between 
the antidepressant-like effect of OEA (Jin et al., 2015) and brain histamine. To this end, we 
evaluated the repeated and chronic i.p. administration of OEA in mice unable to synthesize HA 
due to disruption of the histidine decarboxylase gene (HDC-KO) or to injection of alpha-
fluoromethylhistidine compared to wild type (WT), and saline i.c.v. injected controls in the tail 
suspension test. The phosphorylation level of cyclic AMP-response element binding protein 
(pCREB), a major player in the molecular mechanisms of antidepressant treatment, was also 
evaluated by Western blot analysis in prefrontal cortex and hippocampus, two regions critically 
involved in depression and antidepressant effects of antidepressant compounds. I am the first 
author of the manuscript that is under review at Neuropharmacology. 
In the third part of the thesis I investigated the behavioural effects of OEA in chronic social 
defeat stress (CSDS)-induced cognitive impairments. In 1971 it was reported that brain 
histamine turnover was altered by stress conditions (Taylor and Snyder, 1971). Stress affects a 
constellation of physiological systems in the body and evokes a rapid shift in many 
neurobehavioral processes. In our hypothesis histamine may detect stress-induced signals from 
the periphery. As the influence of OEA on stress reactivity is not currently addressed, we 
evaluated the effect of OEA in HDC-KO and wild type mice subjected to the CSDS. In the 
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CSDS paradigm, experimental mice are exposed to social and physical conflict by aggressive 
member of the same species resulting in both physical and emotional stress for 10 or 21 days, 
while control, non-stressed mice are handled daily. The behavioural repertoire of the animals 
has been assessed at the end of the CDSC, using a battery of tests that are comprehensive of 
several domains affected by stress: social behaviour, mood, anxiety and cognition.  
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Results 
1. Part I- Histaminergic Neurotransmission as a Gateway for the Cognitive 
Effect of Oleoylethanolamide in Contextual Fear Conditioning 
1.1 Materials and Methods  
1.1.1 Animals and Drugs: Male Wistar rats (3 months old, 300–330 g) purchased from 
Envigo (Bresso, Italy) were housed in the animal facility of Ce.S.A.L (Università di Firenze) 
in a temperature-controlled room (22±1°C) with a 12-h-light/dark cycle (light on 7:00 AM to 
7:00 PM), at a constant temperature and humidity with standard diet (4RF21; Mucedola s.r.l., 
Milan, Italy) and freely available water. All procedures were conducted in accordance with 
the Council Directive of the European Community (2010/63/EU) of the Decreto Legislativo 
Italiano 26 (13/03/2014) and National Institutes of Health guidelines on animal care and were 
approved by veterinarian supervision. 
Alpha-FMHis was synthesized at Johnson & Johnson Laboratories (kind gift of Dr. Nicholas 
Carruthers), pyrilamine was purchased from Sigma-Aldrich (UK), and zolantadine and OEA 
from Tocris Bioscience (UK). OEA was dissolved in saline/polyethylene glycol/Tween80 
(90/5/5, v/v), whereas zolantidine and pyrilamine were dissolved in saline. All other reagents 
and solvents were of HPLC grade or the highest grade available (Sigma). 
1.1.2 Surgery: One week after arrival, rats were anaesthetized (75 mg/kg ketamine plus 10 
mg/kg xylazine) and placed on a stereotaxic frame (Stellar; Stoeling, Co., Wood Dale, IL). A 
stainless-steel cannula (22 gauge) was implanted in the lateral ventricle and fixed to the skull 
by using dental cement according to the following coordinates (Paxinos et al., 1998) in mm: 
AP=−0.9; L=−1.5; DV=−2.6 and used for α-FMHis/saline administration. Rats were also 
implanted bilaterally with 22-gauge guide cannulae 1 mm above the BLA according to the 
following coordinates from bregma (Paxinos et al., 1998) in mm: AP = −2.8; L = ±4.9; DV = 
+7.6. Animals were allowed 7 days to recover from surgery before behavioural procedures 
and were handled once daily before the experimental day. 
1.1.3 Infusion Procedure and Experimental Groups: At the time of drug microinfusions, 
the animals were gently restrained by hand, and the injection needle (30 gauge) was fitted 
tightly into the guides, extending 1 mm from the tip of the guide cannulae. The injection 
needle was connected to a 10-μL Hamilton microsyringe, and the infusions were performed at 
a rate of 0.5 μL/30 s. The infusion cannula was left in place for an additional 60 seconds to 
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minimize backflow. The entire bilateral infusion procedure took approximately 90 seconds. 
Alpha-FMHis (5 mM, 1 µL) was infused i.c.v. 24 hours before contextual fear training, and 
controls received equal volumes of sterile saline. Zolantidine (0.1 μM, 0.5 µL side) or 
pyrilamine (0.9 μM, 0.5 µL side) were infused intra-BLA bilaterally immediately after 
training. OEA (10 mg/kg) was injected i.p. 10 minutes after fear conditioning, while controls 
received equivalent volumes of vehicle. 
1.1.4 Contextual Fear Conditioning: Contextual fear conditioning was induced in a Skinner 
box module (29 × 31 × 26 cm, Modular Operant Cage; Coulbourn Instruments Inc.), equipped 
with a grid floor connected to a shock-delivery apparatus (Modular Operant Cage/Grid Floor 
Shocker E13-08; Coulbourn Instruments) and placed in an acoustically insulated room at 
20±1°C. The number of the electric shocks and the inter-shock interval duration was 
predetermined by a stimulus programming device (Scatola di comando Arco 2340, Italy). 
Illumination inside the room was 60 lux. The rat was left undisturbed for 3 minutes and 
subsequently six, 1-seconds 0.8-mA electric footshocks were administered at 30-second 
intervals. The footshock intensity was chosen according to previous published data from our 
laboratory (Benetti et al., 2013). This is a strong enough footshock to guarantee retention at 
72 hours postacquisition without inducing generalization (Baldi et al., 2004). The rat was 
removed 2 minutes after the end of the stimulation, therefore spending a total time of 8 
minutes inside the conditioning apparatus. 
1.1.5 Freezing Measurement: Seventy-two hours after conditioning, rats were again placed 
inside the conditioning apparatus in the soundproof room and left undisturbed for 6 minutes. 
The rats’ behaviour was recorded by means of a closed-circuit television system by an 
experimenter unaware of the animal’s treatment. Freezing was defined as the complete 
absence of somatic motility, with the exception of respiratory movements. Measurements 
were performed with a stopwatch by personnel unaware of the experimental group each 
animal belonged to. Total cumulated freezing time (i.e., total seconds spent freezing during 
each 6-minute period) was calculated and results expressed in seconds of freezing time. All 
behavioral tests were performed between 10:00 AM and 12:00 PM to avoid interference with 
the circadian rhythm (Kamin, 1957). 
1.1.6 Histology: The placement of infusion cannulae was verified postmortem. Rats were 
overdosed with chloral hydrate and the brains removed and stored in 10% formalin for 10 
days. Forty-μm sections were sliced on a cryostat, mounted on gelatine-coated slides, and 
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then stained with cresyl violet for light microscopic observation. Data from rats in which the 
cannulae were not correctly positioned were discarded (<5%). 
1.1.7 Statistical Analysis: All values are expressed as means ± SEM, and the number of rats 
used in each experiment is also indicated. The presence of significant treatment effects was 
determined by a Student’s t test or a 1-way ANOVA followed by Newmann Keuls’ MCT test, 
as appropriate. For all statistical tests, P<.05 was considered significant.  
1.2 Results 
1.2.1 Oleoylethanolamide administration increases freezing time of rats submitted to 
contextual fear conditioning. 
In a first set of experiments we evaluated the effect of OEA (10 mg/kg i.p. a dose that does 
not change motility in the open filed, nor anxiety-like responses, (Campolongo et al., 2009) 
administered within 10 min of contextual fear conditioning in satiated rats. Controls received 
an equivalent volume of vehicle. Retention test was carried out 72 hrs after training. As 
shown in figure 7, an unpaired Student’ t test showed that rats given OEA displayed a 
significant increase of time spent freezing compared with vehicle treated animals (p<0.01).  
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Figure 7. OEA (10 mg/kg) or vehicle (VEH) were injected i.p. 10 minutes after 
contextual fear conditioning. Fear retention was evaluated 72 hours after conditioning. 
Bars represent mean values ± SEM OF 8 TO 10 RATS/GROUP; **P < 0.01; unpaired t test. 
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1.2.2 Histaminergic neurotransmission is required for OEA-freezing enhancements 
To evaluate the role of the central histaminergic system in the cognitive effect of OEA, we 
infused the HDC inhibitor α-FMHis i.c.v. 24 hours prior to fear conditioning. Our research 
group previously showed that administration of α-FMHis quickly suppressed baseline and 
histamine H3 receptor antagonist-evoked release of histamine from the TMN of freely moving 
rats (Benetti et al., 2015), as 180 minutes after injection, histamine release values decreased 
below the sensitivity of the method. OEA (10 mg/kg i.p.) was injected within 10 minutes after 
fear conditioning. Controls received saline i.c.v. and vehicle i.p. One-way ANOVA revealed a 
statistical difference across experimental groups (F3,45=6.756; P<.001; Figure 8). Post-hoc 
analysis with Newman-Keuls MCT showed that OEA increased the freezing time at retention 
test with respect to vehicle-treated rats receiving i.c.v. infusion of saline (P<0.05). However, 
the OEA-elicited potentiation of freezing was abolished in brain histamine-depleted animals 
(P<0.01). Hence, the treatment with α-FMHis 24 hours prior to the test prevented the effect of 
OEA, indicating that the integrity of the central histaminergic system is necessary for the 
effects of OEA on memory consolidation. The freezing time of rats given vehicle i.p. and of 
those receiving α-FMHis or saline i.c.v. did not differ significantly at retention, thus 
indicating that all animals formed a memory trace of the training experience.  
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Figure 8.  α-FMHis or saline was infused i.c.v. 24 hours prior to fear conditioning.  OEA 
(10 mg/kg) or vehicle (VEH) were injected i.p. 10 minutes after contextual fear 
conditioning. Fear retention was evaluated 72 hours after conditioning. Latencies of α-
FMHis groups did not significantly differ from controls. Data are expressed as means ± 
SEM of 10 to 14 animals for each group; ANOVA and Newman-Keuls post hoc 
test, *P<0.05 vs saline (SAL) controls. ##P<.001 vs OEA/SAL. 
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1.2.3 Antagonism of histamine H1 and H2 receptors prevents OEA-induced freezing 
enhancement 
Figure 9 shows the effect of blocking H1 or H2 receptors in the BLA with local, bilateral 
infusions (0.5 µL) of the selective H1 antagonists pyrilamine (0.9 μM) or the H2 antagonist 
zolantidine (0.1 μM), immediately prior to the administration of OEA. Controls received 
intra-BLA, comparable volumes of saline and i.p injections of vehicle. One-way ANOVA 
showed significant differences among experimental groups (F5,64 = 8.436; P<0.0001). Rats 
that received OEA i.p. and saline intra-BLA froze for a significantly longer time at retention 
compared with saline-/vehicle-treated rats (P<0.05) in a comparable manner to the control 
groups shown in Figure 8. However, when either H1 or H2 receptors were blocked, OEA 
administration did not increase the freezing time (P<0.001). Freezing time of rats that 
received vehicle i.p. and pyrilamine or zolantidine in the BLA was not significantly different 
from the freezing time of saline-/vehicle-treated rats. 
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Figure 9.  Rats received bilateral intra-BLA infusions of zolantidine (ZOL), pyrilamine 
(PYR), or saline, and OEA or vehicle i.p. immediately after training. Data are expressed 
as means ± SEM of 9 to 14 animals for each group; ANOVA and Newman-Keuls’ 
posthoc test, **P < 0.01 vs SAL/VEH controls; ###P < 0.001 vs SAL/OEA. 
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1.3 Summary of Results (Part I) 
Emotional arousal enhances consolidation of memory traces, a homeostatic response of our 
organism that is modulated by stress hormones (McGaugh and Roozendaal, 2002). There is 
extensive evidence derived from observations in both experimental animals and humans that 
the amygdala is indispensable to enable the acquisition and retention of lasting memories of 
emotional experiences. The compelling evidence led McGaugh and his collaborators 
(McGaugh, 2004) to propose that the activation of the BLA is fundamental in the 
establishment of an arousal state triggered by fear as unconsciously occurs in humans, 
(LeDoux, 2014) and that arousal is a major component in the establishment of post-training 
memory consolidation.  
By activating peripheral PPAR-α OEA engages the vagus nerve and activates the NTS that in 
turn provides the amygdala, together with the locus coeruleus (LC), with a dense supply of 
norepinephrine, and modulates long term memories (Campolongo et al., 2009). 
The present results show that OEA increases memory expression when tested in the 
contextual fear conditioning paradigm, by increasing the freezing time of treated animals 
compared to vehicle injected rats. Depletion of histamine in the brain with infusion of α-
FMHis that blocks HDC, or intra-BLA infusions of antagonists of the H1 or H2 receptor 
prevent the freezing-enhancing effects of OEA. Therefore, the histaminergic system in the 
amygdala exerts a permissive role on the memory-enhancing effects of OEA. When 
histaminergic neurotransmission is compromised by α-FMHis-induced depletion OEA effects 
on memory expression is prevented. It is relatively surprising that both H1 and H2 receptor 
antagonists produce the same results. The arrangement of these receptors on BLA neurons is 
not known, and explanations may only be speculative. Presumably, when strong aversive 
stimuli are used, all histaminergic inputs to the BLA need to be blocked to prevent freezing-
enhancing compounds such as OEA to exert their effect. 
The concept of several neurotransmitter systems contributing to emotional memory 
consolidation within the same brain region is indisputable (Izquierdo et al., 1992, McGaugh, 
2004, Izquierdo et al., 2016). We think that the emotional arousal that is generally considered 
indispensable for good memory consolidation of fear tasks is provided by both the 
noradrenergic and histaminergic transmission in the BLA. In our hypothesis histamine 
released in the amygdala gates the effects of noradrenaline on BLA neurons, hence blocking 
either neurotransmitter within the BLA would lead to similar behavioural outcomes. In this 
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case, H1 and H2 receptors work synergistically presumably activating common intracellular 
pathways and their blockade leads to similar behavioural outcomes.  
Taking into consideration the results presented in this thesis and previous evidence 
(Campolongo et al., 2009), OEA appears to increase the expression of BLA-dependent 
emotional memory regardless of the type of behavioural response and adverse situation. From 
a translation point of view, few human studies published so far showed that blood 
concentrations of N-acylethanolamides like OEA and other endocannabinoids increase in 
response to acute stress in healthy human volunteers (Dlugos et al., 2012), and subjects 
affected by post-traumatic stress disorder (PTSD) have significantly higher plasma 
concentrations of OEA (Hauer et al., 2013, Schaefer et al., 2014). These results are based on 
small and dis-homogeneous cohort of patients, nonetheless they may have diagnostic 
relevance. In this regard, the results presented in this thesis, suggest that activation of the 
histaminergic system in the BLA has a “permissive” role on the memory enhancing effects of 
OEA. In particular, targeting the H1 or H2 receptor with classical, clinically approved 
antihistamine compounds may modify the expression of emotional memory and reduce 
dysfunctional aversive memories as found in phobias and PTSD. 
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2. Part II- Oleoylethanolamide induces antidepressant-related responses by 
targeting PPAR-α and recruiting the histaminergic neurotransmission 
2.1 Materials and Methods  
2.1.1 Animals and Drugs: Male CD1 mice (25-35 g; Harlan, Italy), histidine decarboxylase 
knockout (HDC-KO) mice and wild type (WT) littermates (background sv129), grown in the 
Centro Sabulazione Animali di Laboratorio (CeSAL), Università di Firenze were used for 
behavioural and biochemical experiments. Genetically modified animals were routinely 
genotyped using the PCR protocol previously described (Provensi et al., 2014). Peroxisome 
proliferator activated receptor-alpha knockout (PPAR-α-KO) mice and wild type (WT) 
littermates (background C57Bl/6), were used for behavioural and biochemical experiments. 
Wild-type and PPAR-α KO (B6.129S4-SvJae-Pparatm1Gonz) mice previously backcrossed 
to C57BL6 mice for 10 generations were bred in Centro Stabulazione Animali di Laboratorio, 
Università Federico II di Napoli, and the colony was established and maintained by 
heterozygous crossing. Mice were genotyped as described on the supplier webpage 
(http://jaxmice.jax.org). Animals were housed in humidity and temperature-controlled room 
(22 - 24 °C), allowed free access to food (4RF21; Mucedola s.r.l., Milan, Italy) and water, and 
kept on a 12-h light/dark cycle (lights start at 7:00 AM). All the experiments were conducted 
between 9:00 AM and 4:00 PM. OEA and vehicle were dissolved as previously reported 
(Result part I). Imipramine (IMI) was dissolved in saline.  Acute neuronal histamine 
deprivation in CD1 mouse was induced by injection intra-cerebro-ventricular (i.c.v) of 5µL of 
α-fluoro-methyl-histamine solution (1µg/µL). The control group received an injection of 5 µL 
of saline ic.v..  
2.1.2 Behavioral Experiments 
2.1.2.1 Tail Suspension Test (TST): Mice were fixed with a 1 cm piece of adhesive tape 
from the tip of the tail, suspended 50 cm from the ground, at least 30 cm away from the 
objects that may surround them and the behavior was filmed by a camera positioned in front 
of the apparatus for 6 min. The immobility time was manually timed by a researcher unaware 
of the treatment. OEA was administered following two different regimens: 10 mg/kg OEA 
repeated administration, 3 i.p. injections in 24 hours and 10 mg/kg i.p. OEA sub-chronic with 
1 daily i.p. injection for 8 days before challenging the mice in TST 1 h after the last treatment. 
The test was carried out in a soundproof room with low light and was recorded using a video 
camera (Digital Cam 34x, Samsung). The time that mice remained immobile (immobility 
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time) in the last 4 minutes of test was analyzed off-line by an operator unaware of the 
pharmacological treatments. 
2.1.2.2 Open Field test: One hour after the last treatment, animals were positioned in a 
corner of an open-field arena (60cm×70cm) and the general motor activity was assessed in a 5 
minutes session. The covered distance (cm) was evaluated using Smart 2.5 software. 
2.1.3 Neurochemical experiments 
2.1.3.1 Western Blot analysis: Male HDC-KO, PPAR-α-KO and WT mice received i.p. 
injections of Vehicle, OEA (10 mg/kg) or imipramine (IMI) (10 mg/kg) daily for 8 days and 
1h later they were challenged in the TST, immediately after the test they were sacrificed. The 
brains were dissected on ice, and the cortices and hippocampi isolated immediately. The 
cortices and the pooled hippocampi (left and right) were individually homogenized in 200 µL 
ice-cold lysis buffer containing protease and phosphatase inhibitors (50mM TrisHCl pH 7.5, 
50mM NaCl, 10 mM EGTA, 5mM EDTA, 2mM NaPP, 4 mM PNFF, 1 mM Na3VO4, 1.1 mM 
PMSF, 20µg/µL Leupeptin, 50 µg/µL Aprotinin, 0.1% SDS) and centrifuged at 12000 rpm at 
4°C for 15 minutes. The supernatant was collected, and total protein levels were quantified 
using the Pierce BCA Protein Assay (Thermo Scientific, USA). Homogenates were diluted in 
a mix of lysis buffer and loading buffer 2x (50mM Tris pH 6.8, 100mM DTT, 10% Glycerol, 
1% Bromophenol Blue and 2% SDS) and boiled for 10 minutes. Aliquots containing 40 µg 
total proteins were resolved by electrophoresis on a 10% SDS-polyacrylamide gel (SDS-
PAGE) and transferred onto polyvinylidene difluoride (PVDF) membranes (Immobilon 
Transfer Membranes, Millipore, USA). Blots were blocked in Tris-buffered saline, pH 7.6 
containing 0.1% of Tween 20 (TBS-T) and 5% non-fat dry milk (Bio-Rad Laboratories, USA) 
for 2h at room temperature and then incubated overnight at 4°C with monoclonal antibodies 
against αpospho-CREB (Ser 133) or αCREB (both from Cell Signaling Technology, USA) 
diluted 1:1000 in TBS-T containing 5% bovine serum albumin or 5% non-fat dry milk, 
respectively. Immunodetection was performed with secondary antibodies (anti-rabbit IgG 
conjugated to horseradish peroxidase, Cell Signaling Technology, USA) diluted 1:5000 in 
TBS-T containing 1% of non-fat dry milk. Membranes were washed in TBS-T and then 
reactive bands were detected using enhanced chemiluminescence (Luminata Crescendo, 
Millipore, USA). Quantitative densitometric analysis was performed using the QuantityOne 
analysis software (Bio-Rad). For each sample the ratio of αpSer133-CREB/αCREB densities 
was calculated and then all the individual rates were expressed as a percentage of the average 
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of ratios obtained from control groups. 
2.1.4 Statistical Analysis: All values are expressed as means ± SEM, and the number of mice 
used in each experiment is also indicated. The presence of significant treatment effects was 
determined by using a 1-way ANOVA followed by Newmann Keuls’ MCT test, as 
appropriate. The level of significance was set at P ≤0,05. 
2.2 Results 
2.2.1 Oleoylethanolamide systemic administration exerts antidepressant-like effect by 
recruiting histaminergic neurotransmission 
We assessed the possible antidepressant-like effect of repeated or sub-chronic OEA treatment 
in the TST response of HDC-KO mice and their wild type littermates (WT). Imipramine was 
used a positive control. 
Figure 10 shows the effect of different doses of OEA administered 3 times in 24 hrs. OEA 
increased immobility time in WT mice at both doses used, whereas it was ineffective in HDC-
KO mice. A 2-way ANOVA revealed an overall significant difference between groups 
F(genotype x treatment) 3,69 = 5.026, p<0.005); F(treatment) 3,69 = 12.85, p<0.0001; F(genot yp e)1,69  = 4.446 
p<0.05.  Bonferonni’s post hoc test showed that OEA treatment at both doses significantly 
decreased the immobility time of WT mice exposed to the TST (5 mg/kg, p < 0.01; 10 mg/kg, 
p<0.001), whereas no significant effects were observed in HDC-KO mice. Imipramine 
decreased the immobility time of both genotypes (WT and HDC-KO, p<0.001; Figure 10A). 
When tested after sub-chronic treatments ANOVA revealed an overall significant difference 
between HDC-KO and WT mice. Either OEA, imipramine or vehicle were administered i.p. 
for 8 consecutive days, and the last injection 1 hr before the test, a 2-way ANOVA showed 
significant differences between groups (F(genotype x treatment) 3,57 = 3.362, p<0.05); F(treatment) 3,57 = 
7.418, p<0.001; F(genotype)1,57 = 10.34 p<0.01). Bonferroni’s post hoc analysis revealed that 
OEA treatment at all doses tested significantly reduced the immobility time of WT mice (5 
mg/kg and 10 mg/kg OEA, p<0.001), whereas no effect on immobility time was observed in 
HDC-KO mice. Imipramine reduced the immobility time of both genotypes (p<0.001; Figure 
10B).  
To avoid biases related to compensatory mechanisms due to chronic depletion of histamine, 
we assessed the effects of OEA in CD1 mice that received i.c.v. infusion of the HDC suicide 
inhibitor α-FMHis. In analogy to the results observed in chronically histamine deprived mice, 
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also in α-FMHis-treated mice, ANOVA revealed an overall significant difference between 
groups (F(7,92) = 14.35; P<0.0001);  In analogy to HDC-KO mice, OEA did not modify the 
immobility time of α-FMHis treated mice (97,4 ± 25,0 s) compared to vehicle-treated mice 
(149,1 ± 18,9 s; Figure 12), whereas imipramine remained effective regardless of the presence 
of brain histamine (F(icv x treatment) 3,79 = 4.707, p<0.01); F(treatment) 3,79 = 43.62, p<0.0001; F(icv) 1,79 
= 5.007, p<0.05). Significant differences for OEA treatments by Bonferroni’s post hoc test 
were p<0.001 (Figure 10C). 
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Figure 10. OEA induce antidepressant-like effects in normal but not in histamine-
deficient mice in the Tail Suspension Test. (A) Effect of systemic administration of OEA 
(repeated regimen) or vehicle to HDC+/+ and HDC-/- male mice (n=5-12).  (B) Effect of 
systemic administration of OEA (10 mg/kg i.p. sub-chronic regimen) or vehicle to 
HDC+/+ and HDC-/-  male mice (n=5-10). (C) Effect of systemic administration of OEA in 
saline or α-FMH (5 µg i.c.v.) injected CD1 mice (n=5-12;*P<0.05; 
**P<0.01;***P<0.001vs SAL/VEH; ANOVA and Bonferroni post hoc test). 
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2.2.2 OEA-induced increase in cortical and hippocampal CREB phosphorylation is 
reduced in HDC-/- mice 
We compared the effect of OEA (10 mg/kg), imipramine (10 mg/kg) and vehicle-treated 
HDC+/+ and HDC-/- mice. Two-way ANOVA showed an overall significant difference 
between groups (F(genotype x treatment) 2,21 = 4.14, p<0.05; F(treatment) 2,21 = 14.05, p=0.0001; 
F(genotype)1,21 = 11.56, p<0.05). Bonferroni’s post hoc test found significant differences between 
groups (p<0.001; Figure 11). OEA increased significantly pCREB in the hippocampus of 
HDC+/+ mice compared with vehicle treated animals (Bonferroni’s post hoc test p<0.01; 
Figure 11A). However, OEA treatment was ineffective in HDC-/- mice (Figure 11A), as 
pCREB levels were not different from those of vehicle treated mice. Similar to the effect in 
the hippocampus, OEA increased pCREB levels in the frontal cortex of HDC+/+ mice (Figure 
11B), but not in the cortex of HDC-/- mice (2-way ANOVA, F (genotype x treatment) 2,24 = 3.78, 
p<0.05; F(treatment) 2,24 = 6.78, p<0.01; F(genotype)1,24 = 3.57, p=0.07). Imipramine administered at 
10 mg/kg for 8 days increased pCREB in the hippocampus and cortex of both genotypes with 
respect to controls (p<0.05). 
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Figure 11. OEA chronic administration increased Ser133CREB phosphorylation in 
hippocampal (A) and cortical (B) homogenates from HDC+/+ but not from histamine-
deprived mice (HDC-/-) challenged in the tail suspension test. (n=5; *p<0,05 **p<0,01 
ANOVA and Bonferroni post hoc test). 
 
- 61 - Results (Part II) 
 
2.2.3 Oleoylethanolamide systemic administration reduced the immobility time by 
targeting PPAR-α  
To explore if PPAR-α are required for the antidepressant-like effect of OEA, PPAR-α-/- mice 
and PPAR-α+/+ littermates were tested in the TST after repeated or sub-chronic OEA (10 
mg/kg) treatments as shown in Figure 12. A 2-way ANOVA was conducted to examine the 
effect of genotype and repeated (3 x in 24hrs) treatment on immobility time that revealed an 
overall significant difference between groups (F (genotype x treatment)1,29 = 5.924, P<0.05; F 
(treatment)1,29=11.80, p<0.01; F(genotype)1.29=0.8, p=0.3). Bonferroni post-hoc test showed that 
OEA treatment significantly decreased the immobility time of PPAR-α+/+ mice (p<0.001), but 
not of PPAR-α-/- mice (Figure 12A). 
When tested after OEA sub-chronic treatments (daily injection for 8 days) ANOVA revealed 
an overall significant difference between groups (F(genotype x treatment)1,27= 9.147; P<0.01; F 
(treatment)1,27=2.94, p=0.09; F(genotype)1.27=0.8, p=0.28). Post hoc analysis revealed a reduction in 
immobility time in WT mice treated with 10 mg/kg OEA compared with VEH treated animals 
(p<0.01;Figure 12B). In PPAR-α-/- male mice no differences were observed between 10 
mg/kg OEA and VEH treated animals (Figure 12B). 
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Figure 12. OEA induces antidepressant-like effects in normal but not in PPAR-α-/- mice 
in the Tail Suspension Test. (A) Effect of systemic administration of OEA (repeated 
regimen) or vehicle to WT and PPAR-α-/- male mice (n=5-12).  (B) Effect of systemic 
administration of OEA (10 mg/kg i.p. sub-chronic regimen) or vehicle to PPAR-α +/+and 
PPAR-α -/- male mice (n=5-10). (**p<0.01 ***p<0.001; ANOVA and Bonferroni MCT). 
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2.2.4 OEA-induced increase in cortical and hippocampal CREB phosphorylation is 
reduced in PPAR-α-/- mice 
Figure 13 shows CREB phosphorylation at Ser 133 residue in cortical and hippocampal 
homogenates of PPAR-α+/+ and PPAR-α-/- mice treated sub-cronically with OEA (10mg/kg) 
or vehicle. Two-way ANOVA revealed an overall difference in hippocampal (F(genotype x 
treatment)1,30=4.943, p<0.05, F(treatment) 1,30 = 10.61, p<0.01; F(genotype)1,30 = 0.6, p=0.44) and 
cortical (F(genotype x treatment)1,26=3.032, F(treatment) 1,26 = 3.514, p=0.09; F(genotype)1,26 = 0.02, p=0.8) 
homogenates between WT and PPARα-KO mice. Post-hoc comparisons showed a significant 
increase in pSer133CREB/CREB ratios after OEA treatment when compared with vehicle-
treated control animals in both the hippocampus (Bonferroni’s post hoc test p<0.01; Figure 
13A) and cortex (Bonferroni’s post hoc test p<0.05; Figure 13B). No significant changes in 
CREB phosphorylation were observed in PPAR-α-/- mice that received OEA or vehicle. 
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Figure 13. OEA chronic administration increased Ser133CREB phosphorylation in and 
hippocampal (A) cortical (B) homogenates from normal (PPARα+/+) but not from 
PPAR-α-deprived mice (PPARα-/-) challenged in the tail suspension test. (n=7-9; *p<0.05 
**p<0.01 2-way ANOVA and Bonferroni post hoc test). 
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2.2.5 General motility 
To exclude possible effects of the various treatments and genotypes on spontaneous 
locomotor activity that may have affected the immobility time in the TST, mice were exposed 
to the open field and motor activity was recorded for 5 min. As shown in figure 14, no 
differences were observed between experimental groups. 
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Figure 14. OEA systemic administration did not change general motor activity in 
normal, HDC-/-  and PPAR-α-/- mice in the open field test.  (A) Effect of systemic 
administration of OEA (10 mg/kg i.p. repeated regimen) or vehicle to HDC+/+ and HDC-
/-  male mice (n=5-11). (B) Effect of systemic administration of OEA (5 or 10 mg/kg i.p. 
sub-chronic regimen) or vehicle to HDC+/+ and HDC-/- male mice (n=5-11). (C) Effect of 
systemic administration of OEA (10 mg/kg i.p.) in saline or α-FMH (5 µg i.c.v.) treated 
CD1 mice (n=8-11). (D) Effect of systemic administration of OEA (10 mg/kg i.p. sub-
chronic regimen) or vehicle to PPAR-α+/+ and PPAR-α-/- male mice (n=5-11; ANOVA 
and Newman- Keuls post hoc test). 
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2.3 Summary of the Results (Part II) 
The present results indicated that repeated treatments with OEA reduced the immobility time 
in the tail suspension test when compared with vehicle treated HDC+/+ mice, but this effect is 
not observed in HDC-/- mice. All antidepressants effectively reduce immobility in this test 
(Lucki, 2001). Imipramine, a classic tricyclic antidepressant, reduced the immobility time in 
both genotypes. To understand if brain histamine is necessary for the behavioural effects of 
OEA, and to exclude compensatory mechanisms in HDC-/- mice, we also evaluated the 
behaviour of mice pharmacologically deprived of histamine by using an i.c.v injection of α-
FMHis, a suicide inhibitor of HDC. Similarly to what we observed in HDC -/- mice, a 
significant reduction in the immobility time was observed in vehicle-treated mice treated with 
OEA, but not in α-FMHis-treated mice. OEA treatments did not modify the exploratory 
behaviour in the open field test performed by each experimental group indicating that the 
effect observed in the TST is not related to alterations in the motor activity.  
We tested the hypothesis that different levels of CREB phosphorylation - a transcription 
factor that serves as a convergence point for multiple classes of antidepressant drugs 
(Carlezon et al., 2005) - would explain the differences between genotypes in the observed 
behavioural tests.  Our results also indicate that histamine signalling is necessary for OEA to 
trigger CREB phosphorylation. By using a sub-chronic treatment regimen, we observed a 
good correlation between behavioural and biochemical data. OEA and imipramine treatment 
reduced the immobility time and increased CREB phosphorylation in cortical and 
hippocampal homogenates of HDC+/+ animals, whereas in HDC-/- mice OEA did not change 
the immobility time, nor CREB phosphorylation levels. Furthermore, imipramine increased 
CREB phosphorylation and reduced immobility time independently of genotype. Our results 
mirror the observation of Munari et al., (2015) who found that selective serotonin reuptake 
inhibitors (SSRI) such as citalopram reduced the immobility time and increased pCREB of 
HDC+/+ mice, but was ineffective HDC-/- mice even though their serotonergic system is 
functional and the pCREB pathway is not compromised (Munari et al., 2015). Thus, our 
biochemical results indicate that the lack of CREB phosphorylation may contribute to OEA 
inefficacy in histamine-deficient mice.  
Where histamine and OEA interact to exert their behavioural and neurochemical effects 
remains to be established. In this thesis, I provide evidence that OEA targets the PPAR-α to 
exerts its effects on the TST and CREB. To this end we evaluated the behaviour of PPAR-
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α+/+and PPAR-α-/- mice. We observed that repeated treatments with OEA reduced the 
immobility time and increased pCREB in WT mice, but not in PPAR-α-/- mice.  
In conclusion, our results confirm that OEA may improve animal depression-like behaviours 
as first observed by Jin et a., (2015) (Jin et al., 2015), but we unravelled a novel mechanism 
by which OEA achieves its effect, namely by recruiting the brain histaminergic system. We 
believe that activation of the histaminergic system, at least in the hippocampus and prefrontal 
cortex, is necessary for OEA-induced CREB phosphorylation and consequently the 
behavioural output. 
Although OEA shows potential as an antidepressant that reverses cerebral functional 
abnormalities and ameliorates depression, further research should be performed on the 
specific pathways by which OEA affects the histaminergic system and behavioural responses. 
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3. Part III- Histaminergic involvement in Oleoylethanolamide protection on 
the cognitive decline induced by chronic social stress in mice 
3.1 Materials and Methods  
3.1.1 Animals and Drugs: Male CD1 mice (9 weeks of age; Charles River, Italy), histidine 
decarboxylase knockout (HDC-/-) mice and wild type (HDC+/+) littermates (background 
c57Bl/6), grown in the Centro Sabulazione Animali di Laboratorio (CeSAL), Università di 
Firenze were used for behavioural experiments. Genetically modified animals were routinely 
genotyped using the PCR protocol previously described (Provensi et al., 2014). Animals were 
housed in humidity and temperature-controlled room (22 - 24 °C), allowed free access to food 
(4RF21; Mucedola s.r.l., Milan, Italy) and water, and kept on a 12-h light/dark cycle (lights 
start at 7:00 AM). All the experiments were conducted between 9:00 AM and 4:00 PM. OEA 
and vehicle were dissolved as previously reported (Result part I). The OEA or Vehicle 
treatments started at ten days before the end of stress procedure.  
3.1.2 Chronic Social Defeat Stress Paradigm: Prior to the social defeat stress, we selected 
the aggressive CD1 resident. CD1 mice were screened for aggressive behavior: latency of first 
attack was monitored and dominance status of mice was visually determined. Mice were 
deemed dominant if they displayed aggressive behavior toward their opponent (another CD1) 
such as tail rattling, chasing, biting and fight-attacks. Mice were submissive if they displayed 
defending and avoidance behaviour such as escaping, defensive response, upright posture and 
defensive immobility. Mice with latencies to attack of >30 s were not selected. The selected 
mice were those that were the most aggressive, most dominant, the heaviest and those which 
had the lowest latency to attack, for two consecutive days. 
Chronic Social Defeat Stress (CSDS), was a 21-days social defeat adapted from previous 
studies (Bartolomucci et al., 2001, Keeney et al., 2006). In this paradigm the  C57Bl/6 mice 
were daily introduced in the cage of CD1 aggressive resident until the first attack. A 3-min 
cut-off for latency of attack was imposed in order to maintain the interaction between mice 
short. Thereafter, mice were physically separated by a perforated transparent divider and 
remained in sensory (olfactory and visual) contact for 2 h. After that the divider is removed 
and the second attack occur. Stresses mice were single housed during the entire period of 
stress. Control mice were left undisturbed housed in their own home cage with other control 
mouse. This chronic stress was combined with overcrowding conditions because housing 
density affects rodent behaviour (Beery and Kaufer, 2015) and crowded social environments 
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have been used as stressors in the protocol. Food consumption and body weight were 
evaluated daily during the protocol.  
3.1.3 Social Interaction Test: The social interaction test is used to assess social behaviour 
(Berton and Nestler, 2006). This is a two-step procedure. In the first 2.5 min session, the 
experimental C57BL/6 mouse is allowed to freely explore an open field arena (41 cm 
length × 32 cm width × 15 cm height). Along one side of the arena is a rectangular (9.5 cm 
length x 7.5 cm width x 5 cm height) wire cage that remains empty during the first trial (target 
absent condition). The C57BL/6 mouse is then removed from the testing arena for 1 minute 
(into a home cage), and a novel CD1 male mouse is placed into the wire cage. In the second 
2.5 min trial (target present condition), the experimental C57BL/6 mouse is reintroduced into 
this arena now containing a social target (unfamiliar CD1 mouse) within the rectangular wire 
cage. Time (sec) spent in the interaction zone (surrounding wire cage) in the presence of the 
social target (Iñiguez et al., 2014), served as dependent variables.  
3.1.4 Novel object recognition test: Object recognition paradigm measures a form of 
memory based on short and unrepeated experiments without any reinforcement, such as food 
or electric shocks (Ennaceur and Delacour, 1988). Object recognition is a one-trial task, and 
does not involve the learning of any rule, being entirely based on the spontaneous exploratory 
behavior of rodents toward objects. Mice were placed in a white polyvinylchloride box 
(70 × 60 cm and 30 cm high) with a grid floor that is easily cleaned, and illuminated by a 75-
W lamp suspended 50 cm above the box. The objects to be discriminated were grey 
polyvinyl  shapes: cubes of 8 cm side, pyramids and cylinders of 8 cm height. The object 
recognition task consisted of a training phase (T1) and a testing phase (T2). Twenty-four h 
prior to T1, they were habituated for two 10 min-session to the experimental apparatus in the 
absence of any object. Each mouse was subjected to the procedure separately and care was 
taken to remove any olfactory/taste cues by cleaning carefully the arena and test objects 
between trials. On the day of the experiment, the mouse was placed for 5 min into the test 
arena facing the same direction and in the same position in the presence of two identical 
plastic objects (cubes) (T1). The behaviour of mice was videotaped, and the time spent 
actively exploring the objects was measured. Exploration was defined as sniffing or touching 
the objects with the nose and/or forepaws. Sitting on or turning around the objects was not 
considered exploratory behaviour. T2 was performed 1 h after T1, during which, each mouse 
was again placed in the test arena for 5 min in the presence of one of the familiar objects and 
a novel object. The position of the objects (left/right) was randomized to prevent bias from 
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order or place preference. Mice were placed in their home cage between trials. The behaviour 
of mice during T2 was videotaped, and the exploration periods of the familiar (F) and the new 
object (N) were measured. Care was taken to avoid place preference and olfactory stimuli by 
randomly changing the role (familiar or new object), and the position of the two objects 
during T2, and cleaning them carefully. Object recognition was carried out in an insulated 
room to avoid any noise that could impair the performance of the mouse.  
3.1.4 Statistical analysis: All values are expressed as means ± SEM, and the number of mice 
used in each experiment is also indicated. The presence of significant treatment effects was 
determined by a 2-way ANOVA followed by Bonferroni MCT test, as appropriate. The level 
of significance was set at P ≤0,05. Statistical analysis was performed using GraphPad 
Software. The data of the object recognition test are expressed as a percentage of time spent 
exploring each object during T1 and T2.  
 
3.2 Results (Part III) 
3.2.1 Chronic Social Defeat Stress induced body weight gain and increased food 
consumption in OEA or VEH treated mice compared to controls  
Figure 15 shows the effect of OEA (10 mg/kg) or vehicle i.p. injections in mice submitted to 
the chronic social defeat stress (CSDS) on body weight and food consumption. Two-way 
ANOVA revealed no statistical significance between groups in WT mice (Figure 15A) nor in 
the HDC-/- mice (Figure 15B).  Figure 15C shows the cumulative food consumption of 
HDC+/+ mice treated with OEA or VEH and subjected to the CSDS protocol. Two-way 
ANOVA revealed no statistical significance between groups. Figure 15D shows the 
cumulative food consumption of HDC-/- mice treated with OEA or VEH and subjected to the 
CSDS protocol. Two-way ANOVA revealed an overall significant difference between groups 
(F(treatments)2,336=198.9, p<0.0001; F(days)20,336=952.76, p<0.0001).  
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Figure15.  Effects of the chronic social defeat stress on body weight and food consumption. 
CSDS (A) induced no significant increase in body weight in OEA and VEH treated stressed mice 
compared with non-+6+stressed control group (n=3-9). (B) No differences were detected in body 
weight between experimental group in HDC-/- mice (n=6-7). (C) CSDS induced no significant 
increase in cumulative food consumption in OEA and VEH treated stressed mice compared with 
non-stressed control group (n=3-9). (D) CSDS induced a significant increase in cumulative  food 
consumption in OEA and VEH treated stressed HDC-/- mice compare to non-stressed controls 
(n=6-7 **p<0.01 ***p<0.0001; 2-way ANOVA). 
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3.2.2 Oleoylethanolamide reduces social avoidance induced by social defeat stress  
Figure 16 shows the effect of OEA systemic administration to stressed animals submitted to 
CSDS compared to controls, in the social avoidance test. OEA was administered for the 10 
days preceding the test. One-way ANOVA revealed an overall significant difference between 
groups (F2,17=20.36 #p<0.05 OEA vs VEH; **p<0.001 OEA vs NON-STRESSED; 
***p>0.0001 VEH vs NON-STRESSED). Stressed mice spent less time in the interaction 
with the CD1 mouse compared to non-stressed control mice, therefore, time spent interacting 
was influenced by stress exposure. OEA treatment increased the interaction time when 
compared to controls treated with vehicle (Figure 16A). On the contrary, ANOVA revealed no 
significant differences among HDC-/- regardless of the treatment either (OEA or vehicle). 
However, an overall significant difference was revealed between stressed and non-stressed 
groups (1-way ANOVA and Bonferroni post-hoc test; F2,18=10.23 *P<0.05 **p<0.001; Figure 
16B) 
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Figure 16. Social defeat stress induced social avoidance in WT and HDC-KO mice. (A) Defeated 
mice spent less time in the interaction compared to controls  (**p<0.001 OEA vs NON 
STRESSED; ***p>0.0001 VEH vs NON STRESSED), OEA treatment increased interaction time 
in defeated animals compared to VEH treated controls (#p<0.05 OEA vs VEH). (B) HDC-/- 
defeated mice spent less time in the interaction compared to controls (*P<0.05 **p<0.001). OEA 
treatment did not increase interaction time in HDC-/- compared to controls. 
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3.2.3 Oleoylethanolamide improves the performance in the object recognition test of WT 
stressed mice, but not of HDC-/- mice 
Figure 17 shows the effect of OEA administration on mice performances in the object 
recognition test. No significant group effects were detected during T1 (two-way ANOVA and 
Bonferroni post-hoc test) (Figure 17A). During T2, given 1 hour after the T1, a 2-way 
ANOVA revealed an overall difference between groups (F (objects x treatment)2,38=1.915 P=0.16; F 
(objects)1,38=18.10, p<0.0001; F (treatment)2,38=6.330e-014, p=1). Non-stressed control mice spent 
more time exploring the familiar object (p<0.001). Similarly, stressed mice treated with OEA 
spent significantly more time exploring the new object than the familiar one (p<0.01). On the 
contrary, 2-way ANOVA revealed no significant differences in the exploration of the two 
objects of stressed mice treated with vehicle (Figure 17B). In HDC-/- mice no significant 
group effects were detected during T1 (2way ANOVA and Bonferroni post-hoc test) (Figure 
17C). During T2 a 2-way ANOVA revealed an overall statistical difference between groups 
(F (objects x treatment)2,31=4.536, P<0.01; F (objects)1,31=0.14, p=0.7; F (treatment)2,31=0.005, p=0.99). 
Non-stressed HDC-/- mice spent more time in the exploration of the novel object compared to 
familiar one (p<0.05). No differences in the exploration of the familiar and the novel object 
were observed in stressed HDC-/- mice treated with OEA or Vehicle (2-way ANOVA and 
Bonferroni post-hoc test; Figure 17D). 
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Figure 17. Effect of OEA on mice performances in the object recognition test. (A) Time spent in 
the exploration of Object A and B during T1 (One -way ANOVA and Bonferroni’s  MCT).  (B) 
T2 was performed 1 h after training. Results are calculated as individual percentage of time 
spent exploring familiar (black columns) and novel (white  columns) objects. One-way ANOVA 
and Bonferroni’s MCT revealed an overall significant difference in the exploration of novel 
object compared to familiar one in non-stressed controls and OEA treated stressed mice (means  
± S.E.M. of 3-9 animals per experimental group. ****P< 0.0001; **p<0.01, vs. respective 
familiar object). (C) Time spent in the exploration of Object A and B during T1 in HDC- /-  mice  
(One-way ANOVA and Bonferroni’s MCT). (D) Percentage of time spent exploring familiar 
(black columns) and novel (white columns) objects in stressed and non-s tressed control mice . 
One-way ANOVA and Bonferroni’s MCT revealed an overall significant difference in the 
exploration of novel object compared to familiar one in non-stressed controls (means ±SEM of 6-
7 animals per experimental group. *p<0.05 vs. familiar object).  
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3.2.4 CSDS did not affect motility of mice tested in the open field 
When evaluated in the open field test ANOVA revealed no significant differences between 
experimental groups after treatments with OEA or VEH in stressed WT mice compared to 
controls (Figure 18). Similarly, HDC-/- mice motility was not affected by stress or treatments. 
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Figure 18. CSDS did not change general motor activity in normal and histamine 
deficient- mice in the open field test.  (A) Effect of CSDS in HDC +/+animals treated with 
OEA (10 mg/kg i.p.) or vehicle compared to non-stressed controls (n=3-7). (B) Effect of 
CSDS in HDC-/- animals treated with OEA (10 mg/kg i.p.) or vehicle compared to non-
stressed controls (n=6-7; 2-wayANOVA and Bonferroni’s post hoc test). 
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3.3 Summary of the Results (Part III) 
Stress and traumatic events are increasingly recognized as risk factors for mental disorders in 
particular for depression, anxiety disorders, and post-traumatic stress disorder (Musazzi et al., 
2017, Selten et al., 2013, Selten and Cantor-Graae, 2007, Selten and Cantor-Graae, 2005) 
(PTSD). Several rodent models of neuropsychiatric disorders use chronic stress, measuring 
behavioural and neurochemical readouts at the end of the protocols.  
The present data indicate that the social defeat stress induce social avoidance behaviour as 
observed by reduction of the interaction time in the social interaction test between stressed 
and non-stressed mice. It has been widely reported that defeated animals of different species 
spend on average significantly less time in close proximity to a social target in a social 
interaction test as compared to non-defeated animals (Berton and Nestler, 2006, Dadomo et 
al., 2011, Hollis et al., 2010). Oleoylethanolamide treatment reduces social avoidance in 
HDC+/+ compared to vehicle treated mice and non-stressed controls. To understand if brain 
histamine is necessary for the behavioural effects of OEA, we also evaluated the behaviour in 
HDC-/- mice. The OEA effect in reducing social avoidance was not observed in histamine 
deprived animals.  
Stress is a biologically significant factor that, by altering brain cell properties, can disturb 
cognitive processes such as learning and memory (Kim and Diamond, 2002). In this 
respect, we showed here that chronic social defeat stress causes memory impairment in 
stressed animals when tested in the object recognition test. Interestingly treatment with 
OEA was able to prevent this deficit, and again histamine was involved also in this effect 
since improvement in recognition memory was not observed in histamine-deficient animals. 
No relevant changes in body weight or food consumption were observed in all groups. 
Therefore, the integrity of central histaminergic system is essential for the OEA to induce 
beneficial effects on stress-related responses. 
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 Conclusions and Discussion 
The histamine system is a pleiotropic system. Histamine plays a major role in the regulation 
of autonomic functions, including energy balance, sleep and regulation of body temperature 
(Haas and Sergeeva, 2012) and is crucial in controlling arousal and cognition (Köhler et al., 
2011). HA-synthesizing neurons are strongly conserved throughout vertebrate phylogeny, 
from zebrafish to humans reflecting the important roles they play in many aspects of 
physiology and behavior (Schwartz et al., 1991, Haas et al., 2008, Haas and Panula, 2003, 
Passani et al., 2007, Panula and Nuutinen, 2013). In mammals, histaminergic neurons are only 
found in the tuberomamillary nucleus (TMN) of the posterior hypothalamus (Watanabe et al., 
1984, Panula et al., 1984) and extend a widespread and diffuse network of unmyelinated 
fibers throughout the central nervous system, including interconnections with other arousal-
related neuromodulatory systems (Panula and Nuutinen, 2013). Disruptions of histaminergic 
neurotransmission have been implicated in a variety of neuropsychiatric disorders (Baronio et 
al., 2014, Shan et al., 2015a, Shan et al., 2015b). The histamine system has been suggested as 
a possible target for the treatment of psychiatric disorders, and drugs that modulate this 
system have been especially proposed as cognitive enhancers (Passani and Blandina, 2011, 
Tiligada et al., 2011). Therefore, a better understanding of the histamine system would be of 
great use for the development of new, much needed, pharmacological treatments for 
psychiatric disorders. 
Oleoylethanolamide is an endogenous lipid mediator that inhibits feeding and in rodents, 
intestinal OEA levels increase about threefold upon refeeding, a response that may contribute 
to the induction of between-meal satiety (Piomelli, 2013). OEA was also identified in the 
gastrointestinal tract of Python molurus (Astarita et al., 2006) suggesting that this lipid 
messenger may be widespread among vertebrate groups and may represent an evolutionarily 
ancient means of regulating energy intake. It was recently demonstrated in our laboratory that 
brain histamine mediates the central effects OEA that is released by the enterocytes in 
response to high fat intake and that reduces eating (Fu et al., 2005) by indirectly activating a 
subpopulation of histaminergic neurons (Provensi et al., 2014).  
In my thesis, I explored other potential interactions between these two phylogenetically 
ancient systems in the pursuit of unexplored neuronal mechanisms that may shed light on the 
mode of action of psychoactive agents and possibly lead to the development of new drugs.  
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OEA was shown to affect not only feeding behaviour, but also the consolidation of aversive 
memories (Campolongo et al., 2009). Here, I demonstrated that the activation of the 
histaminergic system in the amygdala of rats is necessary for OEA to modulate the 
consolidation of fear memories (Provensi et al., 2017).  
As reported in the present thesis we also demonstrated that OEA has a potential antidepressant 
effect since it reduces immobility time in the TST, a paradigm widely used to predict 
antidepressant properties of several compounds. The reduction of immobility time occurred in 
normal but not in histamine-deprived mice. In a parallel fashion, OEA, as other antidepressant 
compounds elicited CREB phosphorylation in normal mice but not in brain histamine-
deprived mice, nor in PPAR-α-/- mice.  
Hence, we provided evidence that the molecular target for the antidepressant-like of OEA is 
PPAR-α. The most conservative hypothesis is that activation of peripheral PPAR-α in turn 
recruits the histaminergic system in a as yet unexplored fashion. Understanding the 
mechanisms of OEA’s antidepressant-like action could improve the understanding of 
depression and the treatment of a disease that is not completely understood and do not 
respond adequately to available agents. 
 
The several roles of OEA in brain disorders led us to test its effects also in stress-related 
disorders. Stress, as previously described, is known to induce physical, behavioural and 
neuropathological outcomes. Here we showed that the maladaptive behavioural responses to 
chronic stress, such as memory impairments and a depression-like phenotype may be 
prevented by OEA sub-chronic treatment. Once again, we evaluated what role the 
histaminergic system play in such effect by considering its involvement in stress responses 
(Ito, 2000). Here, I reported that the beneficial effect of OEA to prevent stress-induced 
behavioural impairments are only achieved in mice with an intact brain histamine system. 
Therefore, in this paradigm as well, brain histamine is necessary for OEA’s neurological 
effect. 
Our current working hypothesis is based on the concept that histaminergic neurons act as a 
relay station that integrate peripheral signals, organize them into a coherent output to selected 
brain regions hence sending information to other brain areas in order to create a neuro-
circuitry responsible for central OEA’s effects. 
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OEA could be just an example, but many other peripheral signals may influence brain 
functions using this mechanism. This hypothesis implies that histamine neurons in the TMN 
are organized in distinct subpopulations differently regulated and innervating specific brain 
areas to allow multiple processes. 
The identification of signalling pathways connecting the periphery with the central nervous 
system is fascinating, and holds great promise for the development of new therapeutics, as 
targeting peripheral systems may provide a more easily accessible therapeutic strategy for 
pharmaceutical treatment.    
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